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THESIS ABSTRACT 
 
MHC II proteins are heterodimeric glycoproteins that form complexes with 
antigenic peptides in order to elicit a CD4+ adaptive immune response. Even 
though there have been numerous MHC II-peptide crystal structures solved, 
there is little insight into the dynamic process of peptide loading. Through 
biochemical and biophysical studies, it has been shown that MHC II adopt 
multiple conformations throughout the peptide loading process.  At least one of 
these conformations is stabilized by the MHC II-like homologue, HLA-DM.  The 
main focus of this thesis is to elucidate alternate conformers of MHC II in an 
effort to better understand the structural features that enable HLA-DM catalyzed 
peptide loading. In this thesis, two altered conformations of HLA-DR were 
investigated, one modeled in the absence of peptide using molecular dynamics, 
and one stabilized by the mutation αF54C. 
The model for the peptide-free form of HLA-DR1 was derived from a 
molecular dynamics simulation. In this model, part of the alpha-subunit extended-
strand region proximal to the peptide binding groove is folded into the peptide-
binding groove such that the architecture of the critical peptide binding pocket, 
P1, as well as the invariant hydrogen bonding network were maintained. 
Biochemical studies aimed at validating the predicted structural changes were 
consistent with the model generated from the simulations. 
  vii  
Next, structural studies were carried out on an MHC II mutant, αF54C, 
which was shown to have unique peptide binding characteristics as well as 
enhanced susceptibility to HLA-DM. Although this mutation did not affect the 
affinity for peptide, there was a striking increase in the rate of intrinsic peptide 
release. Both αF54C and αF54A were over 100-fold more susceptible to HLA-
DM catalyzed peptide release than wild type as well as other mutants introduced 
along the peptide binding groove. In addition, mutation of the αF54 position 
results in a higher affinity for HLA-DM, which, unlike wild type, is detectable by 
surface plasmon resonance. Crystallographic studies resulted in a 2.3 Å 
resolution structure for the αF54C-Clip complex. There were two molecules in the 
asymmetric unit, one of which had no obvious deviations from other MHC II-pep 
complexes and one which had a conformational change as a result of a crystal 
contact on the αF51 residue, a residue which has been shown to be involved in 
the HLA-DM/HLA-DR binding interface. The crystal structure of wild type HLA-
DR1-Clip was also solved, but did not have the altered conformation even though 
there was a similar crystal contact at the αF51. These data suggest the altered 
conformation seen in the mutant structure, results from increased lability in the 
extended stand region due to the αF54C mutation.  As a result of this work, we 
have developed a new mechanistic model for how structural features of MHC II 
influence DM mediated peptide release. 
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PREFACE 
The work presented in this thesis is aimed at describing conformational changes 
that occur in MHC II proteins.  
Chapter I contains background relevant to our understanding of the MHC II 
structure and highlights what is known about MHC II-peptide interactions, MHC II 
structural variability, and MHC II–peptide loading mediated by the accessory 
molecule HLA-DM. 
Chapter II describes a hypothetical model for the peptide free state of HLA-DR1, 
a common MHC II allele. In collaboration with the University of Puerto Rico, a 
molecular dynamics simulation was carried out using the coordinates of a MHC 
II-peptide structure, with the peptide removed. The results from this simulation 
suggest that in the peptide free state, the alpha 50-57 strand region is capable of 
dynamic conformational changes such that it could engage the peptide binding 
groove in an extended conformation much like the canonical peptide structure in 
the bound crystal structure. The most striking feature of this model is that the 
alpha F54 was positioned into the large hydrophobic P1 pocket, much like the 
peptide tyrosine in the bound crystal structure.  The model was evaluated using 
biological probes that have been mapped to regions within the MHC II that were 
predicted to undergo small, moderate or large conformational differences. The 
binding of the probes was in agreement with the conformational changes 
predicted by the model.   
  xvii  
Chapter III describes a HLA-DR1 mutant, αF54C, which is dramatically 
susceptible to HLA-DM mediated peptide exchange, and has a higher affinity 
for HLA-DM as compared to wild type HLA-DR1. The αF54C substitution 
results in a weakening of the N-terminal hydrogen bonds, which were mapped 
using a hydrogen deuterium exchange assay coupled with a novel electron 
transfer dissociation-based mass spectrometry approach. Crystal structure 
analysis of the αF54C in complex with CLIP peptide revealed a conformational 
change in the alpha 310 helical region and adjacent strand region proximal to 
the P1 pocket. The conformational change was seen in only one molecule of 
the asymmetric unit and was induced by a crystal contact at the αF51 position, 
a residue known to be critical for HLA-DM interaction. The αF54C substitution 
increases conformational lability within the extended strand region, such that 
contact at the HLA-DM binding site induces concerted movements along the 
entire alpha 310 helical region. These results thus provide a structural context 
for how HLA-DM may induce conformational changes within MHC II proteins. 
Chapter IV summarizes the work done in this thesis and describes future 
directions that might extend the work presented here. 
Appendix 1 provides an analysis of structural variability in HLA-DQ alleles 
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CHAPTER I 
INTRODUCTION 
ABSTRACT  
Antigen presentation by class II MHC proteins (MHC II) is a critical 
component of the adaptive immune response to foreign pathogens. Our 
understanding of how antigens are presented has been greatly enhanced by 
crystallographic studies of MHC II-peptide complexes, which have shown a 
canonical extended conformation of peptide antigens within the peptide-binding 
domain of MHC II.   However, a detailed understanding of the peptide loading 
process, which is mediated by the accessory molecule HLA-DM (DM), remains 
unresolved. MHC II proteins appear to undergo conformational changes during 
the peptide loading/exchange process that have not been clearly described in a 
structural context. In the absence of a crystal structure for the DM-MHC II 
complex, mutational studies have provided a low resolution understanding as to 
how these molecules interact. This introduction will focus on structural and 
biochemical studies of the MHC II-peptide interaction, and on studies of the DM-
MHC II interaction, with an emphasis on identifying structural features important 
for the mechanism of DM mediated peptide catalysis. 
 
 
 
 
  2  
 
Formation of the MHC II-peptide complex 
MHC II proteins are ~50 kD heterodimeric transmembrane glycoproteins 
that are assembled in the endoplasmic reticulum (Cresswell 1994). The nascent 
complex as expressed in the endoplasmic reticulum is comprised of three alpha-
beta MHC II proteins in complex with the invariant chain (Ii) trimer (Roche, Marks 
et al. 1991; Lamb and Cresswell 1992). The invariant chain has been proposed 
to carry out a dual function to both direct the MHC II to endosomal compartments 
as well as to block the peptide binding groove of the MHC II (Bakke and 
Dobberstein 1990; Roche and Cresswell 1990). In endosomal compartments, 
regions of the Ii that are not protected by the MHC II are proteolyzed by cysteine 
proteases (Morton, Zacheis et al. 1995). This results in an MHC II protected 
peptide fragment, CLass II Invariant chain Peptide (CLIP), which remains bound 
to the MHC II in the antigen binding site (Riberdy, Newcomb et al. 1992). In order 
for antigen presentation to occur, CLIP must be exchanged with endosomal 
peptides, a process which is catalyzed by the MHC II homologue HLA-DM 
(Sloan, Cameron et al. 1995). There is evidence that HLA-DM has a dual 
function to both stabilize an empty conformation of MHC II (Kropshofer, Arndt et 
al. 1997), as well as catalyze peptide exchange (Sherman, Weber et al. 1995), 
as discussed below. Although the involvement of HLA-DM in promoting peptide 
exchange has been definitively described, the mechanism of this process is 
poorly understood (Ferrante and Gorski ; Weber, Evavold et al. 1996; Zarutskie, 
  3  
Busch et al. 2001; Stratikos, Wiley et al. 2004; Narayan, Chou et al. 2007; 
Ferrante, Anderson et al. 2008; Narayan, Su et al. 2009; Zhou, Callaway et al. 
2009).  
 
MHC II structure 
Prior to the first solved MHC II crystal structure, a hypothetical model of 
the MHC II was developed based on the MHC I structure (Brown, Jardetzky et al. 
1988). Genetic analysis had revealed that class I and II molecules shared similar 
domain and genomic organization (Kaufman, Auffray et al. 1984).  It was 
therefore predicted that the MHC II structure would reveal one membrane distal 
peptide binding site that would be comprised of regions with high residue 
polymorphisms (Kaufman, Auffray et al. 1984).  In 1993, a 3.3Å structure of the 
extracellular portion of HLA-DR1 in complex with a mixture of peptides isolated 
from B-cells provided a detailed molecular model describing the fold of the MHC 
II as well as the architecture of the peptide binding groove (Brown, Jardetzky et 
al. 1993). The crystal structure revealed a peptide binding groove that is formed 
by the α1 and β1 domains (Fig. 1.1). The binding groove has a beta sheet floor 
flanked by two alpha helices formed by both the alpha and beta chains. Ig 
domains comprise the membrane proximal portion from both the α2 and β2 
regions (Fig. 1.1).  Although the structures were obtained from soluble 
ectodomains of the protein, there are also alpha and beta chain transmembrane 
domains as well as short cytoplasmic tails that have been implicated in signal  
  4  
FIGURE 1.1 
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FIGURE 1.1.  Crystal structure of MHC II. (a) Cartoon representation of an 
HLA-DR1 peptide complex (1DHL). The alpha chain is shown in salmon, the beta 
chain in teal and the peptide in red. (b) 90° rotation showing the top of the 
peptide binding groove. 
  6  
 
transduction (Nabavi, Freeman et al. 1992). This first structure of an MHC II 
peptide complex revealed that peptides bind in an extended conformation. In 
contrast to the MHC I peptide structures, the MHC II structure showed that the 
peptide binding groove is open ended at both the N and C-terminus of the 
peptide suggesting that peptides of variable length could bind into the groove 
(Brown, Jardetzky et al. 1993). Subsequently, it has been demonstrated that 
MHC II proteins can bind peptides with lengths ranging from 2-4 residues (Sato, 
Zarutskie et al. 2000) all the way to unfolded intact proteins (Lindner and Unanue 
1996). 
In 1994, the crystal structure of HLA-DR1 with a single defined peptide, an 
immunodominant fragment from Heamaglutinin (HA), was solved and the 
molecular details of the peptide MHC II interaction were described (Stern, Brown 
et al. 1994).  The peptide bound in an extended conformation corresponding to a 
type II polyproline twist, in which 35% was solvent exposed and therefore 
theoretically able to interact with CD4+ T-cells. This structure showed pockets in 
the overall peptide binding groove that accommodated five of the thirteen side 
chains from the peptide. In addition, a hydrogen-bonding network was clearly 
defined in this structure, with twelve hydrogen bonds involving the main chain of 
the peptide and conserved residues in the MHC II (Fig. 1.2). Further evidence 
that the hydrogen bond network was a common motif in MHC II–peptide 
interactions was revealed by another MHC II structure bound to a mixture of  
  7  
FIGURE 1.2 
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FIGURE 1.2.  Conserved hydrogen bond network of MHC II. Cartoon 
representation of peptide binding groove, alpha chain in salmon, beta chain in 
teal, peptide in red stick with amine groups colored blue, and carboxyl groups 
colored pink. Conserved residues in MHC II are shown in stick with dashed lines 
representing hydrogen bonds to the peptide backbone. Note that bonds are 
formed between conserved side chains in the MHC II except for the S53, where 
the bonds are mediated by the main chain atoms in the MHC II. The beta 71 
position, represented by a star, is polymorphic. In most HLA-DR alleles, there is 
an h-bond formed between this reside and the carbonyl of the peptide backbone, 
shown as a dashed line, however, in the HLA-DQ, HLA-DP, IA alleles, there is no 
h-bond formed at this position. 
  9  
endogenous peptides determined at higher resolution by co-crystallization 
with a bacterial superantigen, which showed the peptide conformation to be 
constrained by the pattern of side-chain binding pockets as well as by the 
hydrogen bonds that extended from the backbone of the peptide to conserved 
asparagine and glutamine residues on the MHC II (Jardetzky, Brown et al. 1996). 
Through these structural studies, it became evident that there are two 
different aspects of the peptide MHC II interaction. One is mediated through a 
hydrogen bond network that is formed by the peptide backbone and both main 
chain and side chain atoms of the MHC II, and the other mediated by peptide 
side chain interactions with binding groove pockets (Fig 1.2; Fig 1.3 ).  
 
MHC II variation and peptide binding interactions 
There are four main binding pockets present in all MHC II structures 
determined to date, called P1, P4, P6 and P9 that accommodate peptide side 
chains.   These pockets are highly polymorphic and therefore diverse in the 
shape and charge specificity between different MHC II proteins (Fig 1.3). HLA-
DR1 has been extensively studied and numerous structures show a large P1 
hydrophobic binding pocket (Fig 1.4) (Stern, Brown et al. 1994; Jardetzky, Brown 
et al. 1996).  This pocket is the most important determinant of binding specificity 
for HLA-DR1 (Jardetzky, Gorga et al. 1990; Sato, Zarutskie et al. 2000) However, 
there is sequence variation for residues lining the P1 pocket of the MHC II 
proteins, which affects the charge and shape of the pocket, ultimately leading to  
  10  
FIGURE 1.3 
 
 
 
 
 
a 
b 
c 
d 
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FIGURE 1.3. Peptide binding grooves of multiple MHC II show differences 
in peptide side chain specificity pockets. (a) HLA-DR1 (PDB ID: 1DLH) 
Surface representation of the top of the peptide binding groove, with peptide 
shown in stick. Main anchoring specificity pockets P1, P4, P6 and P9 are 
designated below. (bottom) 90° rotation showing side of peptide binding groove 
with peptide side chains lodged into specificity pockets, peptide shown in stck 
and dots.  (b) HLA-DP2 (PDB ID: 3LQZ) shown as in same orientation as (a). (c) 
HLA-DQ8 (PDB ID: 2NNA) shown as in same orientation as (a). (d) HLA-DR3 
(PDB ID: 1A6A) shown as in same orientation as (a). 
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differences in what side chains can be accommodated at this position (Fig. 1.4).  
Indeed, the sequence variations within the peptide binding domain of the MHC II 
proteins cause differences in specificity for the anchor residues all along the 
peptide binding groove (see below) (Fig. 1.3).  
After the first HLA-DR1 structures were solved, the residues forming the 
anchor pockets were defined. Subsequent structures of different MHC II variants 
allowed a detailed look into the effect of polymorphisms and sequence variations 
on the size, shape and specificities of the different pockets. Numerous crystal 
structures for MHC II alleles of HLA-DR, HLA-DP and HLA-DQ have helped to 
refine our understanding of the peptide MHC II interaction (Table 1.1).  In 
addition, crystal structures for I-E the mouse MHC II homologue of the human 
HLA-DR, as well as I-A, the homologue for the human HLA-DQ, have been 
solved (Table 1.1). To date, there are 81 MHC II structures deposited in the PDB, 
encompassing over 15 different allelic variants of the five human and murine 
class II MHC proteins (Table 1.1). Although this is a narrow view into the 
thousands of documented MHC II alleles (Robinson, Waller et al. 2009),  these 
structures are strikingly similar in overall fold with polymorphic differences 
concentrated in the binding groove.  
An example of how MHC II sequence variation can alter the size, shape 
and specificity of the key anchoring pockets was described by Fremont et. al. 
after the crystal structure of the mouse HLA-DR homologue, I-Ek, was solved  
  13  
FIGURE 1.4 
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FIGURE 1.4. Diversity of size and shape of the P1 pocket. Changes in beta 
86/87 contribute to alterations in the size and shape of the P1 pocket. Each of 
the structures are represented in both surface and lines with the beta 86 or 87 
residue shown in stick. The peptide is in purple stick and mesh with the P1 
residue indicated above. (a) HLA-DR1 (PDB ID# 1DLH) has a glycine at beta 86, 
which allows a large hydrophobic pocket at the P1. (b) the HLA-DQ0602 
structure (PDB ID# 1UV6) has a phenylalanine at the beta 87 residue. (c) the IEk 
(PDB ID# 1IEA) has a phenylalanine at the beta 86 position. 
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(PDB ID: 1IEA) (Fremont, Hendrickson et al. 1996). This structure shows that 
polymorphisms in the beta chain give rise to differences along the binding 
pockets. The P1 pocket is smaller in I-Ek due to a phenylalanine at the beta86 
position, which in DR1 is a glycine (Fig 1.4). The beta 86 position forms the side 
of the P1 pocket, so larger residues at this position decrease the volume of the 
pocket, which restricts binding to smaller residues. In I-Ek, the largest pocket is 
the P4. Unlike HLA-DR1, this allows a large hydrophobic residue to be engaged 
in the middle of peptide (Fremont, Hendrickson et al. 1996).  
The beta 86 position also contributes to alterations in the shape of HLA-
DR alleles. For instance, in some HLA-DR alleles, there is a valine at this 
position instead of the glycine found in HLA-DR1. This dimorphism allows 
discrimination between allelic variants of HLA-DR based on the amino acid 
sequence at a single position within a peptide (Newton-Nash and Eckels 1993). 
Other polymorphisms within HLA-DR variants alter structural properties of the P4 
and P6 pockets. For example, differences in charge for residues lining the P4 
pocket in HLA-DR alleles play a role in susceptibility to rheumatoid arthritis (RA) 
(Taneja and David), such that a positive residue at beta71 in HLA-DRB1*0401 
and HLA-DRB1*0101 is linked to RA, but a negative residue as found  in HLA-
DRB1*0402 confers a non-RA associated phenotype.  In addition, polymorphic 
differences extend to the P6 position of HLA-DRB1*0101 which prefers small, 
polar or neutral residues, whereas the DRB1*0401 can accommodate Thr, Asn, 
and Ser (Bolin, Swain et al. 2000). 
  18  
Structures of other MHC II variants have highlighted the diversity in size, 
shape, specificities, and general architecture of the peptide binding groove. The 
mouse HLA-DQ homologue is I-A. One major structural difference between the I-
A/HLA-DQ and the I-E /HLA-DR proteins is due to an alpha 9 glycine insertion 
which contributes to a beta-bulge in the floor of the peptide-binding groove (Fig. 
1.5 b) (Fremont, Monnaie et al. 1998; Scott, Peterson et al. 1998; Zhu, Rudensky 
et al. 2003). Intriguingly, this bulge precludes large anchor residues from 
engaging anchor pockets within the core of the peptide binding groove, while at 
the same time, it draws the peptide deeper into the groove because of additional 
hydrogen bonds that form between the peptide and the main chain atoms of the 
beta bulge residues (Scott, Peterson et al. 1998). Ultimately, these effects allow 
tight binding to peptides that are not anchored by side chain specificity pockets 
within the core of the peptide binding domain (Scott, Peterson et al. 1998). 
HLA-DP2 is the only HLA-DP allele for which a structure has been solved. 
It has a similar charge and shape as HLA-DR1 for the P1 pocket, which can 
accommodate large hydrophobic anchor side chains (Dai, Murphy et al.) (Fig. 
1.3).  However, unlike other HLA-DR alleles, this structure shows that the P6 
pocket is equal in size to the P1 and can also act as a major anchoring site (Dai, 
Murphy et al.). One of the interesting features from this structure is that there is a 
solvent exposed acidic pocket between the peptide backbone and the β-chain α-
helix that is believed to be responsible for the linkage of this allele with Chronic 
beryllium disease (Richeldi, Sorrentino et al. 1993), a T-cell mediated  
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FIGURE 1.5 
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FIGURE 1.5. Structural alignment of MHC II protiens. Crystal structures for 
each of the MHC II proteins with representative alleles are shown aligned by 
residues alpha 4-80 and beta 4-90, which comprise the peptide binding groove. 
The alpha and beta chains are labeled for each panel, and the peptide is labeled 
N’ for the N-terminus and C’ for the C terminus. (a) Ribbon diagram of the top of 
the binding groove for each of the alleles (listed at the bottom by color). (b) 
Ribbon diagram of the N-terminal peptide binding region, asterisk designates 
beta bulge at alpha Gly9 in IA and DQ structures. (c) Same view as in (b) with 
the DQ alleles omitted. (d) same view as in (b) with only DQ alleles. 
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hypersensitivity to beryllium metal, oxides, and alloys {Fontenot, 2001 #767}. 
Structures of other MHC II variants show yet even more diversity in the 
size and shape of the binding groove pockets. The HLA-DQ8 (A1*0301/B1*0302)  
structure (PDB ID: 2NNA), has a P1 pocket that is deep and highly charged. 
However, unlike HLA-DR1, there are deep pockets for the P4 position, which can 
accommodate large hydrophobic residues, and the P9 position, which is deep 
and charged. The P6 pocket is shallow and accommodates only minor anchor 
residues (Lee, Wucherpfennig et al. 2001; Henderson, Tye-Din et al. 2007).  
The crystal structure for HLA-DQ06 (A1*0102/B1*0602), an allele which is 
linked to protection from type I diabetes (Barker 2006), shows significant main 
chain and side chain conformational differences for the alpha 46 to 55 region as 
well as the beta 85 to 91 region. The P1 pocket is shallow as compared to HLA-
DR1, mostly due to a phenylalanine at the beta 87 position, which “fills” the P1, 
much like other alleles which have polymorphisms at the beta 86 position that 
alter the P1 size and shape (Fig. 1.4). This structure reveals fairly equivalent 
sizes and shape for the P4, P6 and P9 pockets (Siebold, Hansen et al. 2004). 
The structure of HLA-DQ2 (A1*0501/B1*0201, PDB ID:1SV9) also 
deviates from the canonical MHC II structure with deviations in the tilt in the 
alpha 45-51 helical region toward the long alpha helical stretch of the alpha 
chain. In addition, the beta 85-91 region is tilted in toward the peptide binding 
domain relative to other MHC II structures. HLA-DQ2 (1SV9) has a region of 
positive electrostatic charge between the P4 and P6 pockets unlike the HLA-DQ8 
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(2NNA) structure, which has a neutral electrostatic potential in this region. The 
P9 can accommodate bulky hydrophobic residues (Kim, Quarsten et al. 2004). T 
There is tremendous diversity within the peptide binding groove of MHC II 
proteins, which in turn allows peptide antigens with variable sequences to bind 
these proteins for presentation to CD 4+ T cells. With the exception of HLA-DR 
alleles (Belmares, Busch et al. 2002), the role that these pocket differences 
confer on the ability of DM to mediate peptide exchange has not been thoroughly 
explored (see below). 
 
Hydrogen Bonding interactions between the peptide and MHC II 
Even though there is great diversity of the residues lining the peptide 
binding groove, highly conserved residues across all MHC II alleles give rise to a 
canonical hydrogen bonding network which provides a peptide sequence 
independent type of interaction (Fig. 1.2, 1.6).  There are however a couple of 
deviations from the canonical network. Notably, the HLA-DQ06 (1UVQ), has a 
rotamer change for the βH81 such that the imidazole group is positioned away 
from the peptide backbone and therefore unable to form a hydrogen bond at this 
position. This structural feature complicates efforts to assign specific functional 
attributes to conserved residues.  Although particular residues may be highly 
conserved, positional changes may alter the functional group associated with that 
residue. The hypocretin peptide in this complex has a proline in the P2 position 
which may induce structural changes that propogate through the protein’s  
  23  
FIGURE 1.6 
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FIGURE 1.6. Conserved hydrogen bond network across multiple MHC II 
proteins. Representative structures from each of the MHC II proteins/alleles that 
have crystal structures were aligned by the alpha1/beta1 peptide binding domain. 
(a) Proteins invariant at positions considered to be part of the “canonical” 
hydrogen bonding network. (b) Proteins that have deviations in the hydrogen 
bond network are overlaid with the invariant alleles, shown as italicized and bold 
to the right. HLA-DQ6 (1UVQ) has a rotamer shift of the betaH81 away from the 
peptide backbone. The IA(u) has tyrosines at the β81 and the β61 and the and 
IA(g7) has a tyrosine at the β61 position.  
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secondary structure (discussed in appendix I). The βH81 position has 
been implicated in peptide binding stability and has been posited as a key 
residue involved in the function of DM mediated peptide exchange (Narayan, 
Chou et al. 2007; Bandyopadhyay, Arneson et al. 2008). However, the βH81 is 
not invariant, for example it is a tyrosine in I-Au (Fig 1.6).  Because the MHC II 
βH81 hydrogen currently is understood to be a major component of the MHC II 
peptide interaction, alleles that can bind peptides without forming this hydrogen 
bond should be more completely characterized. 
 
Conformational changes in MHC II  
Conformational changes have been reported for MHC II proteins 
(Germain and Hendrix 1991; Lee, Kay et al. 1992; Natarajan, Stern et al. 1999; 
Rotzschke, Falk et al. 1999; Schmitt, Boniface et al. 1999; Zarutskie, Sato et al. 
1999; Verreck, Fargeas et al. 2001; Carven, Chitta et al. 2004; Carven and 
Stern 2005). Although direct structural analysis of MHC II peptide complexes 
suggest a highly stereotypic structure for these proteins, biochemical data does 
exist for alternate conformers under conditions that differ primarily in peptide 
occupancy and pH. Evidence for a peptide loading induced conformational 
change suggests that prior to peptide loading, empty MHC II exist in a “floppy” 
conformation (Germain and Hendrix 1991; Rotzschke, Falk et al. 1999). 
Peptide empty MHC II are less stable in SDS such that the subunits of the 
empty MHC II dissociate and migrate as individual chains, whereas MHC II in 
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complex with stably bound peptide migrates as an intact complex (Stern and 
Wiley 1992).  
Peptide loading has been shown to alter the apparent molecular weight 
as assessed by gel filtration, which changes from 50kDa, for MHC II in complex 
with stable peptide to 60kDa, for empty MHC II (Zarutskie, Sato et al. 1999). 
Since the actual molecular weight of the peptide complex is larger than the 
empty protein, the larger apparent molecular weight for the empty protein 
implies that there is a difference in shape.  In addition, a change in 
hydrodynamic radius from 37.4 Å for empty MHC II, to 31.8 Å for MHC II-
peptide complex has been observed (Zarutskie, Sato et al. 1999). Studies using 
far-UV circular dichroism (CD) spectroscopy suggest that peptide empty MHC II 
exists in a conformation that has slightly less helical content (Rabanal, Ludevid 
et al. 1993; Zarutskie, Sato et al. 1999).  
In addition to peptide-induced variations in MHC II structure, there is 
evidence that pH may play a role in MHC II conformational changes. The 
relevance of this pH change is likely due to the acidic environment of the 
endosome where peptide exchange occurs. The effect of pH on MHC II 
conformation has been partially attributed to increased peptide binding at low 
pH (Jensen 1990; Sadegh-Nasseri and Germain 1991). In endosomal 
compartments (pH ~5), exposure to peptides that can form stable MHC II 
peptide complexes decreased the floppy conformation, noted above, and 
promoted an SDS stable conformation of the complex (Sadegh-Nasseri and 
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Germain 1991). In addition, there are changes in the far-UV spectrum for MHC 
II under acidic conditions as compared to spectra taken at neutral pH, 
suggesting that there is loss of helicity for MHC II under acidic conditions (Lee, 
Kay et al. 1992; Reich, Altman et al. 1997). A histidine at position alpha 33 has 
also been implicated as a pH “trigger” for MHC II conformational changes 
(Rotzschke, Lau et al. 2002). When the alpha His 33 is mutated to a tyrosine, a 
relatively isosteric analogue that is unable to undergo protonation at endosomal 
pH, the stability of the peptide-MHC II complex is unaffected by changes in pH 
(Rotzschke, Lau et al. 2002).  
 Although the aforementioned studies suggest that MHC II can undergo 
alterations in conformation as a result of peptide binding and/or changes in pH, 
they do not reveal the regions of the MHC II that are involved. Studies designed 
to better understand which regions of the MHC II participate in peptide induced  
changes have subsequently been carried out and include epitope mapping of 
antibodies specific for empty MHC (Carven, Chitta et al. 2004), differential 
chemical modification due to peptide occupancy (Carven and Stern 2005), as 
well as molecular dynamics simulations of the peptide free form of MHC II 
(Painter, Cruz et al. 2008). These studies will be described below. 
Using a panel of monoclonal antibodies raised against the denatured beta 
chain of HLA-DR1 and screened for preferential reactivity against peptide-empty 
vs. peptide-loaded HLA-DR1, Carven et al was able to map regions along the 
beta chain of HLA-DR1 that had different activity when the MHC II complex was 
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empty or loaded with peptide. Antibodies that reacted differentially to empty and 
peptide loaded HLA-DR1 were mapped to two distinct regions along the beta 
chain. One set of antibodies mapped to the alpha helical region in the beta 1 
domain from the 53-73 positions; notably, this region is kinked, with the L53 
pointing down toward the peptide binding groove which is seen in structures of 
HLA-DR peptide complexes. In order for there to be a recognizable epitope at the 
L53, there presumably would have to be an alteration of this region that exposed 
that residue. The other region that was recognized by the empty, but not peptide 
loaded HLA-DR1 mapped to the membrane-proximal C-terminal region of the 
beta chain and encompassed residues 186-189. The implications of having this 
region differentially recognized is that the conformation of the empty protein must 
have differences that propagate to regions far away from the peptide binding 
domain (Carven, Chitta et al. 2004). 
Carven et al continued to define differences in conformation between 
empty and peptide loaded MHC II by probing for differential reactivity towards 
selective chemical modifications between the bound and unbound complexes 
(Carven and Stern 2005). Here, they determined differential reactivity for a 
residue in the alpha chain proximal to the P1 pocket, Arg 50, as well as 2 other 
residues, βR198 and βK98, which mapped to the same lateral face of HLA-DR1 
that is predicted to be at the binding interface between MHC II and HLA-DM.   An 
additional residue in the alpha chain, K67, was also observed to be differentially 
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reactive between the empty and peptide loaded structures (Carven and Stern 
2005). 
In addition to identifying regions and residues thought to be involved in the 
peptide induced conformational change for MHC II proteins, studies using 
molecular dynamics simulations, as well as normal mode analysis, of the peptide 
free MHC II, have been performed (Nojima, Takeda-Shitaka et al. 2003; Painter, 
Cruz et al. 2008; Yaneva, Springer et al. 2009). These studies have implicated 
the beta 57-67 residues, described as a region differentially recognized in empty 
MHC II by monoclonal antibodies above, as well as the short 310 alpha helix and 
adjacent strand region of the alpha chain, which is proximal to the P1 pocket, as 
undergoing conformational changes during peptide loading. In chapter II of this 
thesis, a molecular dynamics study is presented which enabled the development 
of a model for the peptide free state of MHC II in which the alpha 50-59 region 
partially unwinds and engages the peptide binding groove, with the αF54 
repositioning into the P1 pocket.  
The conformational changes described in the aforementioned studies 
are based on HLA-DR alleles. However, an overlay of the structures for 
different MHC II alleles reveal that even in the peptide bound form there are 
regions that can adopt alternate conformations, some of which are beyond the 
side chain specificity pockets (Fig. 1.5). The beta chain helical region has a 
distinct kink, which has been implicated as a region that undergoes 
conformational changes based on peptide occupancy, as described above.  
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However, even in the peptide bound form, the position of this kink can move 
toward or away from the peptide binding groove (Fig. 1.5). In addition to this 
variable conformation on the beta chain, the alpha 310 helical region can adopt 
alternate conformations in the HLA-DQ alleles (Fig. 1.5). Intriguingly, the HLA-
DQ0602 structure (1UVQ; A1*0102/B1*0602) and the HLA-DQ1 (3PL6; 
A1*0102/B1*0502) have the same alpha chain, yet have alterations in the 
conformation of the alpha 310 helix (Fig. 1.7). The HLA-DQ2 (1SVP; 
A1*0501/B1*0201) also deviates from the majority of MHC II structures in the 
310 helical region (Fig. 1.5).  A comparative analysis of the differences between 
the HLA-DQ alleles as well as implications for the differences therein, are 
discussed in Appendix I. 
 
HLA-DM 
Human Leukocyte Antigen-DM (DM), H-2M in the mouse, is an MHC II-
like alpha beta heterodimer that is structurally homologous to classical MHC II 
proteins (Fig. 1.8) (Mosyak, Zaller et al. 1998). The structure of DM revealed 
that it is comprised of two Ig membrane proximal domains, αl2/β2, and two 
membrane distal domains that contain two anti-parallel alpha helices that flank 
a beta sheet platform (Fremont, Crawford et al. 1998; Mosyak, Zaller et al. 
1998). Although DM shares only 28% sequence identity with the MHC II allele, 
HLA-DR1, the structural similarities between the two molecules are striking. 
The crystal structure of DM has the same overall fold as DR1 with one obvious  
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FIGURE 1.7 
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FIGURE 1.7.  The alpha 310 helical region can adopt alternate conformations 
even in HLA-DQ alleles that contain the same alpha chain. (top) LSQ 
alignment, between the HLA-DQ structures, 1UVQ and 3PL6 (both contain the 
same alpha chain), of the C-alpha atoms for residues in the 310 alpha helix. 
(middle) The same alignment was performed for the HLA-DQ structure 1UVQ vs. 
the HLA-DR1 structure, 1DLH. (bottom) The same analysis is shown for the HLA-
DR1 structure, 1DLH and the HLA-DQ structure 3PL6. In all cases, there is a 
deviation in RMSD in the 310 helical region. 
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deviation, the region which constitutes the peptide binding domain of HLA-DR1 
is partially collapsed, leaving only a vestigial P4 pocket, and is devoid of 
peptide (Fig 1.8) (Fremont, Crawford et al. 1998; Mosyak, Zaller et al. 1998)  
HLA-DM is an endosomal resident that is necessary for proper antigen 
presentation by MCH II proteins (Morris, Shaman et al. 1994). As noted above, 
in the absence of DM, most MHC II remain occupied with CLIP indicating that 
the repertoire of peptides displayed at the cell surface requires the catalytic 
action of DM (Denzin, Robbins et al. 1994; Morris, Shaman et al. 1994). The 
individual crystal structures of DM and MHC II reveal no obvious docking site, 
although analysis of the DM structure did reveal a tryptophan rich hydrophobic 
cluster on one lateral face of DM that was proposed to be binding sites for 
either MHC II and/or HLA-DO, an inhibitor of DM catalyzed peptide exchange 
(Mosyak, Zaller et al. 1998). Several subsequent studies have aimed at 
identifying the DM-MHC II interface, as described below. 
The mechanism through which DM mediates peptide catalysis remains 
to be elucidated. However, various functions of DM have been described. DM 
acts as a chaperone to protect peptide free MHC II from forming inactive 
aggregates (Stern and Wiley 1992; Denzin, Hammond et al. 1996; vogt, 
Moldenhauer et al. 1997). In addition, DM promotes peptide exchange from 
MHC II (Morris, Shaman et al. 1994; Vogt, Kropshofer et al. 1996; Weber, 
Evavold et al. 1996), and increases peptide binding to “empty” MHC II 
(Grotenbreg, Nicholson et al. 2007). Given the structural differences between  
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FIGURE 1.8 
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FIGURE 1.8. Crystal structure of HLA-DM. (a) Cartoon representation of  HLA-
DM (PDB ID# 2BC4). The alpha chain is shown in brown, the beta chain in blue. 
(b) 90° rotation showing the top of the closed groove that corresponds to the 
peptide binding groove in other MHC II proteins. 
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empty and loaded MHC II, and the roles for DM in promoting peptide exchange 
and stabilizing empty protein, one might expect that DM interacts specifically 
with particular conformations of MHC II.  
. 
Identification of the DM-MHC II interface 
Given that there is no co-crystal of the DM-MHC II complex, nor 
structural information regarding the dynamic nature of this interaction, studies 
have focused on identification of key residues and regions involved in the DM-
MHC II interaction in order to gain insight into the mechanism of peptide 
catalysis.  Early work aimed at identifying interaction sites for DM on MCH II 
was presented by Doebele et al (Doebele, Busch et al. 2000), in which random 
mutagenesis of both chains of the MHC II allele, HLA-DR3, was performed in 
order to test which residues were important for the DM-MHC II interaction. 
Using a screening method for cell surface HLA-DR3 bound CLIP, in an DM 
deficient cell line, this group identified HLA-DR3 mutations that led to elevated 
cell surface expression of CLIP, and were therefore not able to undergo DM 
induced peptide exchange.  The results implicated one lateral face of HLA-
DR3, (Doebele, Busch et al. 2000) (Fig 1.9).  
Looking at other regions of both MHC II and DM proteins, Weber et al 
investigated the role of the transmembrane and cytoplasmic domains of DM 
and MHC II which were determined to be of importance only in colocalization of  
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FIGURE 1.9 
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DM-MHC II interactions. (a left) Ribbon diagram of the top of the peptide binding 
domain of HLA-DR1 with the alpha chain in salmon, the beta chain in tela and 
the peptide in red. The P1 tyrosine of the peptide peptide in shown in spheres. 
Curve represents regions implicated in the DM-MHC II interaction, with brief 
descriptions noted. Stars represent residues found to be important in the DM-
HLA-DR3 interaction. (a right) Side view of the HLA-DR1 peptide complex 
depicted on the left with residues important in the DM-HLA-DR3 interaction 
indicated as stars, bracket indicates the lateral face of HLA-DR thought to be at 
the interface with DM in the DM-MHC II complex. (b) Ribbon diagram depicting 
the putative DM HLA-DR binding interface 
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the two proteins within the same membrane, i.e. and not involved in the 
mechanism per se (Weber, Dao et al. 2001).  
Due to the low affinity of soluble DM and MHC II (Busch, Reich et al. 
1998), and the recent evidence that tethering to the membrane by both 
molecules was necessary for optimal DM mediated peptide catalysis, Busch et 
al (Busch, Pashine et al. 2002) devised a system whereby DM and HLA-DR 
could be tethered in parallel orientations that would differentially bring opposing 
lateral faces of the molecules in close proximity with each other (Busch, 
Pashine et al. 2002). This was accomplished by tethering leucine zippers to 
either alpha or beta chains of each protein with variable linker distances. This 
work further established that the lateral face implicated in earlier mutagenesis 
work to be at the interface between DM and MHC II. In addition, the orientation 
which leads to optimal DM mediated peptide catalysis suggested that the HLA-
DR and DM beta chains were in closer proximity than either of the alpha chains 
(Fig. 1.9). 
Further details regarding the orientation of DM and MHC II emerged 
from work carried out by Stratikos et al (Stratikos, Mosyak et al. 2002). This 
group tethered either the N- or C-termini of antigenic peptides to a free cysteine 
β46 on DM, and tested the ability of DM to “exchange” the tethered peptide on 
HLA-DR1.  When the N-terminal peptide/DM complex was used, exchange 
rates were several orders of magnitude greater then when the C-terminal 
tethered peptide, or untethered peptide was used. This finding established the 
  40  
N-terminal peptide binding region of the MHC II to be involved at the interface 
between these molecules, thus supporting work implicating this lateral face 
(Fig. 1.9).  
Providing further information on the orientation of the DM-MHC II 
complex, another study used mutagenesis of DM residues to reveal that there 
was a lateral face on DM that contained residues important to the DM-MHC II 
interaction (Fig. 1.9) (Pashine, Busch et al. 2003). This work helped to 
unequivocally define the faces of DM and MHC II that were involved at the 
interface during peptide catalysis. However, taken together, the studies outlined 
here, establish only a low resolution structural model for the DM/ MHC II 
complex. 
The P1 pocket MHC II has been implicated also as important in the DM-
MHC II interaction. The flexibility of the P1 pocket has been postulated by Chou 
et al as a key structural determinant of DM susceptibility (Chou and Sadegh-
Nasseri 2000). They proposed that when the P1 pocket is empty and/or flexible, 
DM can recognize the MHC II and induce a peptide receptive state. From this 
work, the flexibility rather then the stability of the complex was introduced as a 
determinant for DM action (Chou J. ex med 2000) (Fig. 1.9).  
Using a panel of peptides that were unable to form various hydrogen 
bonds along the peptide backbone, Stratikos et al (Stratikos, Wiley et al. 2004) 
determined that hydrogen bonds that formed between the N-terminal region of 
the peptide and conserved residues of the MHC II, proximal to the P1 pocket, 
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were critical determinants of DM action. When these bonds were broken, DM 
catalysis of peptide release was augmented up to an order of magnitude 
(Stratikos, Wiley et al. 2004) (Fig. 1.9).  
Recently, a new model has been proposed that suggests DM recognition 
of MHC II peptide complexes only occurs for MHC II that have a vacant P1 
pocket as well as disrupted N-terminal hydrogen bonds (Anders, Call et al.). In 
this model, spontaneous protein motions in the N-terminal region of the peptide 
would eject the peptide from the P1 pocket, providing a novel MHC-pep 
complex that DM could recognize. Although this is the most recent model put 
forth for the mechanistic action of DM, by no means does it provide a complete 
understanding of the catalytic role of DM, which remains still unresolved.  
The functional studies described above were limited to HLA-DR alleles, 
however there are conformational differences in regions of HLA-DQ alleles that 
lie at the presumptive DM-MHC II interface (Fig 1.5, Fig 1.9). It has been 
established that DM has different susceptibility for allelic variants of HLA-DR 
(Belmares, Busch et al. 2002), and there are hints that HLA-DQ structural 
differences may play a role in DM susceptibility (Fallang, Roh et al. 2008), 
however a thorough examination of HLA-DM susceptibility for non-HLA-DR 
MHC II proteins has not been fully explored and would be necessary for a 
comprehensive understanding into the nature of DM mediated peptide 
catalyses.   
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In summary, structural analysis of the individual molecules, mutagenesis 
studies, and biochemical characterization of the DM-MHC II interaction have 
elucidated key components of the DM-MHC II interaction, however, details that 
would enable a full understanding of the peptide exchange process remain 
elusive. In chapter III of this thesis, studies of  an MHC II point mutant, αF54C 
HLA-DR1, show dramatic increases in DM susceptibility and affinity as well as 
a conformational change in the same regions as those seen in some of the 
HLA-DQ alleles (see appendix I). These studies have identified lability within 
the MHC II 310 alpha helix and adjacent strand region as a key structural 
determinant for DM mediated peptide exchange.  
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ABSTRACT 
Major histocompatibility complex proteins are believed to undergo significant 
conformational changes concomitant with peptide binding, but structural 
characterization of these changes has remained elusive. Here we use molecular 
dynamics simulations and experimental probes of protein conformation to 
investigate the peptide-free state of class II MHC proteins.  Upon computational 
removal of the bound peptide from HLA-DR1-peptide complex, the α50-59 region 
folded into the P1-P4 region of the peptide binding site, adopting the same 
conformation as a bound peptide. Strikingly, the structure of the hydrophobic P1 
pocket is maintained by engagement of the side chain of Phe α54. In addition, 
conserved hydrogen bonds observed in crystal structures between the peptide 
backbone and numerous MHC side chains are maintained between the α51-55 
region and the rest of the molecule.  The model for the peptide-free conformation 
was evaluated using conformationally-sensitive antibody and superantigen 
probes predicted to show no change, moderate change, or dramatic changes in 
their interaction with peptide-free DR1 and peptide-loaded DR1.  The binding 
observed for these probes is in agreement with the movements predicted by the 
model. 
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INTRODUCTION 
Class II major histocompatibility complex (MHC) are heterodimeric 
proteins which bind antigenic peptides as part of the adaptive immune response 
to foreign pathogens. Upon binding peptides derived from endosomes or the 
extracellular milieu, the intact MHC II-peptide complex is displayed at the cell 
surface of antigen presenting cells (APC) for surveillance by CD4+ T-cells 
(Trombetta and Mellman 2005) Interaction between the APC and its cognate 
CD4+ T-cell leads to an effector response which then clears the body of the 
invading pathogen. 
Peptides bind to the MHC II in an extended polyproline type II helix along 
a binding groove contributed to by both the alpha and beta subunits. Crystal 
studies of allelic variants bound to a variety of peptides has revealed a conserved 
hydrogen bonding network which exists between the peptide backbone and main 
chain residues along the helices of the alpha and beta binding domain 
(McFarland and Beeson 2002). Additionally, binding energy is created by the 
interaction of peptide side chains and pockets within the binding groove of the 
MHC II binding domain. Residues lining these pockets vary between alleles 
which thus lead to tremendous diversity within the peptide repertoire.  Generally, 
these pockets accommodate residue side chains from the peptide at the P1, P4, 
P6 and P9 positions with smaller pockets or shelves in the binding site 
accommodating the P3 and P7 residues; these pockets are numbered along the 
peptide relative to a large usually hydrophobic pocket near the peptide binding 
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site.  For HLA-DR1, DRB1*0101, (DR1), a common human class II MHC protein 
and the subject of this study, the P1 pocket shows a strong preference for large 
hydrophobic side chains (Trp, Tyr, Phe, Leu and Ile), the P6 pocket has a strong 
preference for smaller residues (Gly, Ala, Ser and Pro) and the P4 and P9 
pockets have weaker preference for residues with some aliphatic character 
(Stern, Brown et al. 1994) 
Although there is little structural variation observed among crystal 
structures determined for MHC II-peptide complexes, numerous studies have 
reported alternate conformations for particular MHC II-peptide complexes 
(Schmitt, Boniface et al. 1999; Kasson, Rabinowitz et al. 2000; Doebele, Pashine 
et al. 2003; Lovitch and Unanue 2005) and for peptide-free MHC II molecules 
(Zarutskie, Sato et al. 1999; Hansen, Lybarger et al. 2005). Peptide-free DR1 has 
been shown to have a larger hydrodynamic radius than the peptide loaded form 
(29 vs 35 Å), as well as a decrease in helicity as measured by circular dichroism  
(Zarutskie, Sato et al. 1999; Sato, Zarutskie et al. 2000). These differences are 
reversed upon binding peptide.  Peptide binding and dissociation experiments 
have shown that peptide-free MHC II can adopt two interconverting forms, one 
receptive to and one averse to peptide loading  (Rabinowitz, Vrljic et al. 1998; 
Natarajan, Assadi et al. 1999; Joshi, Zarutskie et al. 2000). The receptive state is 
able to bind peptide rapidly, but will convert to the peptide averse form within 
minutes if not stabilized by peptide or by association with the chaperone HLA-DM 
(DM).  It has been proposed that DM mediates its function by shifting the 
  47  
equilibrium of peptide averse to a peptide receptive state; however, the peptide 
loading process is still relatively undefined (Zarutskie, Busch et al. 2001; 
Grotenbreg, Nicholson et al. 2007). In order to gain a better understanding of this 
process, it is necessary to develop a more detailed understanding into the 
structural changes that exist based on peptide occupancy.  
Previous work using conformationally sensitive monoclonal antibodies 
raised against the β chain of DR1 has revealed that a noncontiguous epitope in 
the peptide binding region (residues β53-67) and another in the lower Ig-like 
domain (residues β186-189) are accessible only in the peptide-free conformation 
(Carven, Chitta et al. 2004). Another study which used differential chemical 
modification found residues α50, 67, β98,189 were selectively modified in 
peptide-free but not peptide-loaded DR1 (Carven and Stern 2005). Although 
these studies helped to define regions within the structure that change upon the 
peptide occupancy state, there is not enough information to generate a working 
model of the peptide-free DR1.  Molecular dynamics simulations have been used 
to gain insight into conformational changes relative to an experimentally defined 
structure (Zheng, Brooks et al. 2007; Laberge and Yonetani 2008). Combined 
with experimental support, models developed from this method can be 
substantiated.  In this study, we performed molecular dynamics simulation of 
DR1 in both the peptide-free and peptide-loaded states. Several regions of DR1 
were predicted by this analysis to change conformation substantially upon loss of 
bound peptide.  Differential binding of conformationally-specific antibody and 
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superantigen probes to the peptide-free and peptide-loaded forms of DR1 
provides experimental support for this model.  
 
RESULTS 
Modeling the structure of the peptide-free form of HLA-DR1 by molecular 
dynamics 
A model for the peptide-free structure of DR1 was obtained by molecular 
dynamics simulation starting from the X-ray coordinates of a DR1-peptide 
complex (PDB Code: 1SJE, (Zavala-Ruiz, Strug et al. 2004)) from which peptide 
was removed before the start of the simulation.  A parallel simulation was started 
from the same coordinates but without the removal of peptide.  Simulations were 
carried out in a water-filled box at constant temperature and pressure using the 
GROMOS force field (Berdensen 1995) and 2 fs time steps.  During the 
simulation, the total root mean square deviation, RMSD, from the starting 
coordinates was followed in various regions of the protein, Fig. 2.1a-1c. Large 
changes in RMSD were observed over the first 5-10ns, particularly in the a1b1 
peptide binding domain and the lower b2 immunoglobulin-like domain, with much 
smaller fluctuations occurring thereafter. The models were investigated in detail 
at the 10ns time point, as described below. 
RMS fluctuations during the first 10ns of the peptide-loaded and peptide-
free simulations are shown in Fig. 2.1d and e as a function of residue number. A 
trajectory of the simulation is depicted in Fig. 2.1f for the peptide-free and in  
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FIGURE 2.1 
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FIGURE 2.1  Molecular dynamics simulation of peptide-bound and peptide-
free DR1. (a-c) RMS deviation over time for the peptide-loaded (red) and 
peptide-free (black) simulations, for the a1b1 peptide-binding  domain (a), the Ig-
like α2 domain (b), and the  Ig-like β2 domain (c).  (d-e) Root mean square 
(RMS) fluctuation during the simulation for each residue (all atoms included) for 
the α (d) and β (e) subunits. (f-i) Molecular dynamic trajectories for the peptide-
loaded (f,h) and peptide-free (g,i) form of DR1.  Initial states shown in blue, final 
states shown in red, with a linear interpolation of conformations between the 
initial and final structures shown in other colors.  (f,g), Side view of entire protein, 
(h,i)Top view of peptide binding site only. 
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Fig. 2.1 g for the peptide-loaded dynamics runs.  Panels h and i show a different 
view highlighting the peptide binding region. In the peptide-binding site, 
significant movements can be seen in the α-helices of the peptide-free form, as 
compared to those of the peptide-loaded form, which do not fluctuate or move as 
much. In the α subunit, the principle differences between the peptide-loaded and 
peptide-free simulations were in the region α34-60 (light arrows).  This region, 
part of the peptide binding domain, corresponds to the last two strands of the 
beta sheet “floor” and the first half of the helical region forming one side of the 
peptide binding site.   In the β subunit the largest RMS fluctuations were in the 
lower β2 immuoglobulin domain, residues β90 – 110, and were observed in both 
peptide-loaded and peptide-free simulations (Fig. 2.1c and e, asterisk). Different 
orientations of the β2 domain relative to the peptide binding domain already have 
been observed in different HLA-DR1 crystal structures, reflecting orientational 
flexibility in this domain (Fig. 2.2). Elsewhere in the β-subunit, large RMS 
fluctuations were observed for the region β50-70 in the peptide binding site. In 
this region larger deviations were observed in the peptide-free as compared to 
the peptide-loaded simulation (Fig. 2.1f-i). A difference distance matrix plot 
(Schneider 2000) calculated at 10ns highlights the regions that are different in 
this simulated peptide-loaded and peptide-free forms (Fig. 2.3).  
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FIGURE 2.2.  Conformational variation in DR1 crystal structures.  (a) 
Overlay of  crystallographically distinct αβ heterodimers from three crystal 
structures reported for DR1-peptide complexes solved in the absence of a 
protein that helps DR1 crystallize, superantigen.  (b) RMS  Cα distances for 
aligned αβ  `heterodimers, with mean RMS in each domain indicated.  
Structures aligned using LSQMAN   
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FIGURE 2.3 
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FIGURE 2.3.  Difference distance matrix between the peptide-loaded and 
peptide-free conformations of HLA-DR1.  The blue squares show areas in the 
protein that move away from each other in the peptide-free model when 
compared to the peptide-loaded conformation, with stronger blue intensity for the 
areas that are the further apart (15Ǻ difference) and lighter blue for the areas that 
move away but not as much (4Ǻ difference).  The red squares show regions on 
the peptide-free form that move closer to other regions in the protein when 
compared to peptide-loaded HLA-DR1; intense red color are areas that move 
more.  The gray squares are regions that do not change as much (0-3.99 Ǻ).     
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Motion of the α50-59 region into the amino-terminal end of the peptide binding 
site 
 The major conformational alteration observed during the simulations is a 
narrowing of the N-terminal region of the peptide-binding site (Fig. 2.4 a).  This 
narrowing of the site occurred early during the dynamics simulations run in the 
absence of peptide, and persisted throughout the entire 60ns time course.  Such 
narrowing was not observed during dynamics simulations of the peptide-loaded 
form (Fig. 2.4 b), although at late time points (>15ns) the peptide-loaded 
simulation occasionally sampled conformations having some characteristics of 
the peptide-free form (not shown). In the model of the peptide-free form of DR1 
derived by molecular dynamics simulation, the peptide binding site is dramatically 
altered as compared to the highly stereotyped conformation observed in crystal 
structures of the peptide-bound form. During the simulation, the α50-59 region of 
DR1 moves to fill the amino-terminal end of the peptide-binding site occupying, in 
part, the area where the antigenic peptide is usually found (Fig. 2.5).     The 
amino-terminal region of the peptide-binding site of DR1 was previously 
suggested to be more flexible upon peptide-removal in a normal mode analysis 
(Nojima, Takeda-Shitaka et al. 2003) as well as in another molecular dynamics 
calculation (Gupta, Hopner et al. 2008). In our model, a sharp kink forms at Gly 
α58, allowing the region α50-59 to fold into the binding site, taking the place of 
the bound peptide in the P1 to P4 region.  Smaller changes but still significant  
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FIGURE 2.4  Motion of α50-59 into the peptide binding site during 
molecular dynamics in the absence of peptide  (a), Ribbon diagram of 
peptide-free DR1 before and after molecular dynamics simulations, showing 
residues at N-terminal end (magenta, α52-57 and β79-83), central region (green, 
α62-66 and β65-69), or C-terminal end (blue, α71-75 and β58-62) of peptide 
binding site, used to calculate distances across the binding site (indicated by 
arrows).  (b) Changes during molecular dynamics simulation of distances across 
the peptide binding site at three different locations, colored as indicated in panel 
(a). 
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FIGURE 2.5 
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FIGURE 2.5 Molecular dynamics model of peptide free HLA-DR1 (a) Ribbon 
diagram of DR1 (blue) bound to the HA-peptide. The peptide is shown as stick 
with carbon atoms in white; and nitrogen and oxygen atoms in blue and red, 
respectively. Pocket locations within the peptide-binding site are labeled. (b) 
Ribbon diagram of the peptide-free HLA-DR1 (red). (c,d), hydrogen-bonding 
interactions for the peptide-loaded (c) and peptide-free (d) proteins. (e,f) Surface 
side-view of the N-terminal region of the peptide-binding site for the peptide-
loaded (e) and peptide-free (f) proteins. In (d and f), α50-59 of the peptide-free 
form is shown in stick representation as for the HA peptide. Figures were 
generated using PyMol.  
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changes are observed in the helical regions that flank α50-59, in the adjacent 
α46-49 loop, and in beta subunit helical regions (compare Fig. 2.5 a and b). 
After moving into the peptide-binding site, the main chain of the α50-59 
region is able to satisfy essentially all of the hydrogen bonds in this region lost 
upon removal of the peptide.  In the conserved arrangement observed in class II 
MHC-peptide crystal structures, the backbone of a bound antigenic peptide forms 
six hydrogen bonds with the side chains of non-polymorphic DR1 residues Gln 
α9, Arg β71, His β81 and Asn β82 (Fig. 2.5 c).  In the molecular dynamics model 
of the peptide-free form of DR1, each of these hydrogen-bonding interactions is 
observed, by direct hydrogen bonding between the main chain atoms of DR1 
α53-57 and side chains of Gln α9, Arg β71, His β81 and Asn β82 (Fig. 2.5 d). 
Movement of the α50-59 region into the peptide binding site also results in 
occupancy of the P1-P4 side-chain binding pockets.  These pockets line the 
peptide binding site, and accommodate side chains of the bound peptide.  The 
P1 pocket of DR1 is the major determinant of peptide binding, and usually 
accommodates a large hydrophobic side chain (Sato, Zarutskie et al. 2000). In 
the molecular dynamics model of the peptide-free form of DR1, the side chain of 
Phe α54 binds into the P1 pocket, in the same orientation as observed for an 
aromatic P1 residue from a crystal structure of peptide-loaded DR1 complexes 
(Fig. 2.5e and f).    The P4 pocket is shallower than the P1 pocket and open at 
the end, and in DR1 exhibits a weaker preference for residues with some 
aliphatic character. In the molecular dynamics model of the peptide-free form of 
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DR1, the side chain of Gln α57 binds into the P4 pocket, essentially identically to 
Gln at the corresponding position in a bound peptide.   
 
Experimental probes of conformational differences between peptide-free and 
peptide-loaded HLA-DR1  
We attempted to evaluate whether or not the striking alterations predicted 
by the molecular dynamics simulations corresponded to actual conformational 
differences between peptide-free and peptide loaded proteins, using 
conformation-specific superantigen and antibody probes of DR1 structure.  
Superantigens are soluble bacterial toxins that bind to class II MHC proteins and 
T cell receptors, causing polyclonal T cell activation independent of peptide 
antigen (Sundberg, Deng et al. 2007).  Superantigen binding sites on the DR 
alpha subunit have been determined by X-ray crystallography of superantigen-
MHC-peptide complexes (Sundberg, Andersen et al. 2003), but superantigen 
binding to peptide-free DR1 has not been described.  Conformation-specific 
antibody probe of DR1 structure also are available, although the binding sites 
have been characterized only by domain-swap or mutagenesis experiments.  In 
general, most of these antibodies bind to both peptide-free and peptide-loaded 
DR1 (Stern and Wiley 1992). MEM-264 and the related MEM-265, MEM-266, 
and MEM-267 antibodies (Carven, Chitta et al. 2004) are exceptions to this 
pattern, in they preferentially bind to peptide-free DR1 (Carven, Chitta et al. 
2004). Although differential binding to peptide-free and peptide-loaded DR1 has 
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been described for these antibodies, there has not been a quantitative 
comparison.  Finally, LB3.1, a commonly used anti-DR antibody, also has been 
reported to exhibit differences in reactivity with peptide-free and peptide-loaded 
DR1 (Carven, Chitta et al. 2004), although again a quantitative analysis has not 
been reported.  To evaluate in a quantitative manner the differential binding of 
these conformationally-specific superantigen and antibody probes, we used 
surface plasmon resonance (SPR) to characterize their binding to peptide-free 
and peptide-loaded DR1 prepared by refolding purified DR1 alpha and beta 
subunits in the absence or presence of peptide (see Methods).  As previously 
observed (Zarutskie, Sato et al. 1999), the peptide-free and peptide-loaded 
preparations exhibited characteristic differences in hydrodynamic radius and 
stability to SDS-induced subunit dissociation (Frayser, Sato et al. 1999) (Fig. 
2.6). 
Staphylococcal Enterotoxin C3 (SEC3)  The interaction of the bacterial 
superantigen SEC3, a tight-binding derivative of staphylococcal enterotoxin C3 
(SEC3), with peptide loaded DR1 has been characterized previously by X-ray 
crystallography and SPR experiments (Anderson and Gorski 2003) Contact 
residues between SEC3 and peptide-loaded DR1 have been mapped by 
crystallography and by mutagenesis, and include Tyr13, Asp17, Gln18, Met36, 
Ala37, Leu60, Ile63, Ala64, and Lys67 on the α chain (Sundberg, Andersen et al. 
2003). None of these residues move appreciably during molecular dynamics 
simulation of the empty protein. To evaluate this experimentally, peptide-free and  
  64  
FIGURE 2.6 
  65  
FIGURE 2.6  Characterization of peptide loaded and peptide-free DR1.   (a) 
analysis of peptide-free DR1 and peptide-loaded DR1 by gel filtration (Superdex 
200). Peptide-free DR1 (dotted line) has a larger hydrodynamic radius than the 
peptide-loaded DR1(solid line). Arrows indicate position and molecular weight of 
standard proteins. X axis represents time in minutes, Y axis represents optical 
density (milli Au).  (b) 12% SDS-PAGE analysis of peptide-free DR1 and peptide-
loaded DR1.  Peptide-free DR1 dissociates into alpha and beta subunits in SDS 
whereas peptide-loaded DR1 is resistant to SDS dissociation until boiled. 
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peptide-loaded DR1 were immobilized to a streptavidin-dextran surface using a 
C-terminal biotin (Cochran and Stern 2000) and binding to varying concentrations 
of soluble SEC3 was followed by SPR.  Essentially identical SEC3 binding 
behavior was observed for peptide-free and peptide-loaded DR1 (Figure 2.7 a-c).   
SPR data were fit to a kinetic model, yielding apparent KD values for peptide-free 
and peptide-loaded DR1 of 14 µM and 11 µM, respectively.  Equilibrium analysis 
of these same data yielded apparent KD values of 6.1 and 8 µM. These values 
are similar to a previously reported KD value for peptide-loaded DR1 binding to 
SEC3, 4.6 µM (Andersen, Lavoie et al. 1999) To confirm these results, we 
performed this experiment in the opposite orientation, with SEC3 immobilized via 
standard amine coupling and with peptide-free or peptide-loaded DR1 in the 
mobile phase. Again, we obtained similar KD values for peptide loaded and 
peptide-free DR1 6.0 and 6.1 µM, respectively (Table 2.1).  Overall these data 
demonstrate that SEC3 binding does not distinguish between peptide-loaded and 
peptide-free DR1. Because this epitope is not predicted to move upon release of 
peptide, these observations are consistent with the model. 
Monoclonal antibody MEM-264  MEM-264 is a monoclonal antibody that 
previously has been shown to bind specifically to the peptide-free conformation 
of DR1 (Carven, Chitta et al. 2004).The MEM-264 epitope has been mapped by 
overlapping peptides and alanine scanning mutagenesis, and corresponds to a 
discontinuous region on the β subunit helical region including residues 53-67 
(Carven, Chitta et al. 2004). In the molecular dynamics model for peptide-free  
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FIGURE 2.7  Binding of peptide-loaded and peptide-free DR1 to 
conformationally sensitive probes. (a-c) SEC3 binding to immobilized bio_DR.  
(a) SPR using peptide-loaded DR1.  b) SPR using peptide-free DR1. Residuals 
shown below SPR traces (c) Equilibrium RU values vs. DR concentration, open 
circles, peptide-free DR1, closed triangles, peptide-loaded DR1. (d-f) DR1 
binding to immobilized MEM264. (d) SPR using peptide-loaded DR1.  (e) SPR 
using peptide-free DR1. (f) ELISA of MEM264 binding empty, open circles, and 
loaded, closed triangles, DR1. (g-i) DR1 binding to immobilized LB3.1. (g) SPR 
using peptide-loaded DR1. (h) SPR using peptide-free DR1.Residuals shown 
below. (i) ELISA of immobilized LB3.1 binding to peptide-free (open circles) and 
peptide-loaded (closed triangles) DR1. (j-k) Comparison of experimental to model 
data.  (j)  Ribbon diagram of the peptide-binding site of DR1, colored by peptide-
free to peptide-loaded  Cα distances at the end of the dynamics runs.  Larger 
distances shown in darker red.  (k) same view but colored to indicate sites of 
conformational probe interaction: The yellow region represents DR1 residues that 
interact with the superantigen SEC3, magenta resides that interact with the 
conformationally sensitive antibody LB3.1, and blue residues in the peptide-free 
protein that interact with the antibody MEM264 specific for the peptide-free 
protein. 
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DR1, this entire region is predicted to move significantly relative to the rest of the 
β subunit. We performed a SPR binding analysis with immobilized MEM-264 and 
either peptide-free or loaded DR1 in the mobile phase (Fig. 2.7 d and e). We 
found robust binding to immobilized MEM-264 for peptide-free DR1, with an 
apparent KD of approximately 24 nM.   Peptide-loaded DR1 did not bind to MEM-
264 at concentrations up to 2µM.  In addition, we compared binding of peptide-
free and peptide-loaded DR1 using an equilibrium sandwich ELISA assay (Fig. 
2.7 e).  Half maximal binding of peptide-free DR1 to MEM-264 was observed at 
5.3 nM, whereas no binding was observed for peptide-loaded DR1 at 
concentrations up to 2mM. Overall these data suggest that peptide-loaded DR1 
binds to MEM-264 at least 400-fold more weakly than does peptide-free DR1.  
Monoclonal antibody LB3.1  LB3.1 is a conformationally sensitive monoclonal 
antibody which has three residues known to be important in the binding 
interaction, all in the loop region proximal to the α50-59 strand (Fu and Karr 
1994). During the simulation, Gln α18 does not move appreciably, Met α36 
moves ~5Ǻ but similarly in the peptide-loaded and peptide-free models, and Lys 
α39 moves and packs differently against the alpha-subunit helix in the peptide-
free and peptide-loaded models. Of these, Gln α18 and Met α36 also are in the 
SEC3 epitope.   Differential binding of LB3.1 to peptide-free and peptide-loaded 
DR1 has been observed previously (Carven, Chitta et al. 2004) but not 
quantified. We used SPR and ELISA to quantify differences in LB3.1 binding to 
peptide-free and peptide-loaded DR1.  SPR analysis using immobilized LB3.1 
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and serial dilutions of peptide-loaded and peptide-free DR1 indicated a significant 
difference in binding kinetics (Fig 2.7 g and h), with tighter binding of the peptide-
loaded form.  Kinetic analysis revealed apparent KD values of 76nM for peptide-
loaded DR1 and 2.3nM for peptide-free DR1.   We used ELISA to evaluate the 
binding interaction under equilibrium conditions (Fig. 2.7 i).  Once again, tighter 
binding of LB3.1 to the peptide-loaded form was observed, with half-maximal 
binding observed at 0.47 nM and 2.1 nM for the peptide-loaded and peptide-free 
species respectively (Table 2.1). Overall, these experiments confirm that peptide-
free and peptide-loaded DR1 have distinct binding affinities for LB3.1.  
 
DISCUSSION 
Previous work has shown that peptide-free and peptide-loaded forms of 
DR1 have different physical characteristics, including hydrodynamic radius, 
chemical and thermal stability, and far-UV CD and near-UV fluorescence spectra 
(Zarutskie, Sato et al. 1999). In general, these changes can be induced by 
binding a wide variety of peptides regardless of length, affinity, or sequence 
characteristics, provided that the P1 site is occupied (Chou and Sadegh-Nasseri 
2000; Sato, Zarutskie et al. 2000).These observations support the notion that 
there are conformationally distinct forms of the protein based on peptide 
occupancy (Sadegh-Nasseri, Stern et al. 1994; Boniface, Lyons et al. 1996; 
Runnels, Moore et al. 1996; Rabinowitz, Vrljic et al. 1998; Natarajan, Assadi et 
al. 1999; Zarutskie, Sato et al. 1999). Our goal in this work was to gain insight 
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into structural changes that can occur in the absence of bound peptide. Because 
conditions for crystallization of peptide-free DR1 have yet to be determined, it is 
necessary to approach structural questions by alternative methods. Using 
molecular dynamics in conjunction with experimental data can help to elucidate 
particular structural events that might otherwise remain obscure. 
Two important features of the interaction of peptides with class II MHC 
proteins have been identified: hydrogen bonds between conserved MHC 
residues and the peptide main chain amides, and binding of several peptide side 
chains into pockets in the MHC peptide binding site (McFarland and Beeson 
2002). Hydrogen bonding interactions involving the peptide N-terminal region in 
general appear to be more important than those involving the C-terminal region 
(McFarland and Beeson 2002), and for DR1 variants the P1 pocket dominates 
the overall peptide binding behavior (Sato, Zarutskie et al. 2000). In the 
molecular dynamics model for the peptide-free form of DR1, the key hydrophobic 
P1 pocket becomes engaged by Phe α54, and the secondary pocket P4 by Gln 
α57. Conserved MHC hydrogen bonding residues along the peptide binding 
groove become engaged by the α50-59 loop region. By the end of the simulation, 
the peptide-free DR1 has satisfied all of the N-terminal binding interactions that 
were lost by initial removal of the peptide in a manner consistent with the original 
bonds made by the peptide-DR1 interaction. 
We used conformationally-dependent antibody and superantigen probes 
in order evaluate the concordance of the model with experimental data. Overall, 
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there is good agreement between the predicted MHC backbone movement and 
the degree to which the probes are sensitive to the presence or absence of 
peptide (Fig. 2.7 j and k). The SEC3 epitope is predicted to remain stationary, 
and our data show no significant differences in binding to peptide-loaded and 
peptide-free DR1. The MEM264 epitope overlaps with an area in the peptide 
binding region predicted to undergo a large global movement upon peptide 
release, and previous results (Carven, Chitta et al. 2004) and those shown here 
demonstrate a dramatic difference in the reactivity of this antibody for peptide-
loaded and peptide-free DR1. The LB3.1 epitope has not been comprehensively 
mapped, although a few residues within the epitope have been identified using 
DR-IE (human-mouse) chimeric molecules (Fu and Karr 1994). Residues Gln 
α18 and Met α36 are also included in the SEC3 epitope, but Lys α39 is unique to 
the LB3.1 epitope.  This residue undergoes a rigid body as well as a side chain 
reorientation movement in the model. Partial shielding of the residue could 
account for the observed difference in LB3.1 binding to peptide-free and peptide-
loaded DR1, although it is possible that other residues not yet identified 
contribute to LB3.1 binding. Overall, the observed binding to peptide-free and 
peptide-loaded DR1 for each of the conformational probes that we tested was 
consistent with predictions from the molecular dynamics models for the peptide-
free protein. While this concordance indicates that molecular dynamics may 
provide a useful model for the peptide-free conformation, none of the available 
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conformational probes directly addresses the key prediction of motion of α50-59 
into the peptide binding site, which remains to be validated experimentally.   
Peptide-free DR1 has been shown to exist in at least two kinetically 
defined states, peptide receptive and peptide averse (Rabinowitz, Vrljic et al. 
1998; Natarajan, Assadi et al. 1999; Joshi, Zarutskie et al. 2000; Sato, Zarutskie 
et al. 2000). The peptide receptive form is observed immediately after release of 
a bound peptide, and is characterized by rapid binding of added peptide.  In the 
absence of peptide, the peptide-receptive form converts to the peptide-averse 
form, with t1/2 ~ min (Rabinowitz, Vrljic et al. 1998). The peptide-averse form 
binds peptide much more slowly, in a process that requires a slow unimolecular 
conformational change (Joshi, Zarutskie et al. 2000). The predicted 
conformational change in the peptide-free model could account for the peptide 
averse form of DR1. It is plausible that upon peptide release, the binding groove 
is not obstructed and therefore could bind subsequent peptide directly, whereas 
once the peptide binding groove is engaged by the α50-59 region, the protein 
would be in the peptide-averse form, and would have to undergo a 
conformational change in order to allow space for the peptide to enter the binding 
groove.  
In addition to catalyzing peptide binding and release, the peptide 
exchange factor HLA-DM has also been shown to stabilize the peptide-receptive 
form of MHC II and to prevent conversion to the inactive form (Pierre, Denzin et 
al. 1996; Kropshofer, Arndt et al. 1997; Zarutskie, Busch et al. 2001; Grotenbreg, 
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Nicholson et al. 2007). A key residue in the interaction with DM and DR1 is DR1 
Phe α51. When Phe α51 is mutated to Val or Ser the catalytic ability of DM is 
abolished (Doebele, Busch et al. 2000). Interpreting this result in light of the 
dynamics model, interaction of DM with this residue could prevent the α50-59 
region from engaging the peptide binding groove, inhibiting formation of the 
averse form. Interestingly, occlusion of the P1 pocket of DR1 by Glyβ86Tyr also 
has been reported to abolish DM activity (Chou and Sadegh-Nasseri 2000; 
Narayan, Chou et al. 2007). Such a mutation might prevent α50-59 closing into 
the peptide binding site, and in fact reduced formation of a peptide-averse state 
has been reported for this mutant (Chou and Sadegh-Nasseri 2000; Narayan, 
Chou et al. 2007). 
The structures of class I and class II MHC proteins are similar, despite 
having different domain/subunit organizations and different modes of peptide 
binding (Brown, Jardetzky et al. 1993). The α50-59 region, proposed herein to 
occupy the HLA-DR peptide binding site in the absence of peptide, represents a 
prominent difference between the structures of class I and class II MHC proteins 
(Brown, Jardetzky et al. 1993). In class I MHC proteins, the α1 helix continues 
unbroken through this region, extending from residue 56 (equivalent to HLA-DR 
α52) to residue 86 (equivalent to HLA-DR α78), whereas in class II MHC 
proteins, this region is an extended strand interrupting flanking helical regions.  
This structural difference may be related to differences in the conformational 
changes induced in the absence of peptide, which have been characterized for 
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both class I (Fahnestock, Tamir et al. 1992; Bouvier and Wiley 1998) and class II 
MHC proteins (Zarutskie, Sato et al. 1999).  A crystal structure of a class I MHC 
protein with a pentapeptide epitope occupying only the C-terminal end of the 
binding site (Glithero, Tormo et al. 2006) and molecular dynamics studies of 
peptide-free class I MHC proteins (Zacharias and Springer 2004; Sieker, 
Springer et al. 2007) suggest that for class I MHC proteins the N-terminal side of 
the peptide binding site could be conformationally stable in the absence of 
peptide, with conformational changes predicted in the C-terminal end (Zacharias 
and Springer 2004; Sieker, Springer et al. 2007). By contrast, crystal structures 
of class II MHC-peptide complexes carrying truncated penta-, hexa-, and  hepta-
peptide analogs occupy the N-terminal side of the peptide binding site, leaving 
the C-terminal end empty but not conformationally altered (Bolin, Swain et al. 
2000). Recently, a study of dipeptide-triggered ligand exchange of DR1 
suggested that short peptides can prevent closure of the N-terminal side of the 
peptide-binding site predicted by molecular dynamics to occur in the absence of 
peptide (Gupta, Hopner et al. 2008). Finally, normal mode analysis of DR1 and 
HLA-A2 (Nojima, Takeda-Shitaka et al. 2002; Nojima, Takeda-Shitaka et al. 
2003) also highlighted differences between their potential dynamic motions, with 
the N-terminal side of the binding site predicted to be more flexible for class II 
MHC proteins and the C-terminal side more flexible for class I MHC protein.   
In summary, this work presents a molecular model for the conformational 
change induced by peptide removal from an MHC II protein. The model was 
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derived from molecular dynamics calculations and tested using experimental 
conformational probes. Development of a model for the peptide-free form of DR1 
can help to interpret the conformational changes known to occur within the 
protein during peptide binding and release, and can provide insight into possible 
mechanisms for DM action. 
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METHODS 
Generation of DR1: 
DR1 was expressed, purified and folded as previously described (Frayser, Sato 
et al. 1999). Briefly, the extracellular domains of DR1 subunits were expressed 
individually as inclusion bodies in Escherichia coli.  Subunits were purified by 
anion exchange chromatography and then diluted into folding buffer in the 
presence or absence of a 5 fold molar excess of the HA peptide 
(PKYVKQNTLKLAT).  Folded peptide-free or peptide-loaded DR1, was purified 
by affinity chromatography on an LB3.1-protein column and by gel-filtration 
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chromatography to remove any aggregated protein.  Pooled fractions were 
concentrated to 1mg/ml and stored at 4ºC.  For some SPR studies, DR1 with a 
cysteine modification at the C-terminus of the alpha subunit was prepared by 
expression in insect cells as previously described (Cochran and Stern 2000). 
Briefly, DR1-acys was expressed in S2 insect cells in serum free medium and 
purified from culture supernatant by LB3.1 affinity and gel filtration 
chromatography. This material is substantially free of peptide (Stern and Wiley 
1992). To generate loaded complex, purified DR1acys was incubated with excess 
peptide in binding buffer (100mM phosphate pH 5.0, 0.02% NaN3, 1 mM EDTA, 
50mMNaCl, 0.05% octyl glucoside, 2mM dithriothreitol (DTT), 0.01mg/ml PMSF) 
for 3 days at 37ºC.  Peptide-free and peptide-loaded DR1acys were purified as 
described above for E. coli derived protein. 
 
ELISA: 
A sandwich ELISA was used to measure binding of peptide-free or peptide-
loaded DR1 to LB3.1 and MEM264 as previously described (Stern and Wiley 
1992). Plates were developed with ABTS and read on a Polarstar plate reader 
(BMG Labtech) at 405 nm absorbance. Half-maximal binding concentrations 
were obtained from a 4 -parameter binding equation fit to the data.  
 
Biacore: 
We used a BIAcore 2000 surface plasmon resonance biosensor for the SEC3 
experiments and a Biacore 3000 for all other SPR experiments (Biacore AB, 
Uppsala, Sweden). Biotinylated DR1 was immobilized using Sensor Chip SA.  All 
other experiments used standard carbodiimide-mediated amine coupling to 
Sensor Chip CM-5.  Data were background-subtracted using an unmodified 
reference surface.  The data were fit to the 1:1 binding with baseline drift model 
provided by BiaEval software.   Fit residuals are shown in Fig. 4, and generally 
represent <10% of the overall signal. The LB3.1 and MEM264 were regenerated 
with 20mM NaOH for 1.5 or 1 minutes respectively, followed by a 2 minute 
stabilization in running buffer.  For the other SEC3 and DR1 surfaces, bound 
protein eluted rapidly and a separate regeneration protocol was not needed. 
 
 
Molecular Dynamic Simulation: 
Each simulated system consisted of one protein molecule in a cubic box with a 
distance of 3.0 nm from its periodic image, with approximately 30,200 molecules 
of water.  Coordinates for the peptide-bound form of DR1 were downloaded from 
the Protein Data Bank (PDB code: 1SJE) (Zavala-Ruiz, Strug et al. 2004). The 
peptide-free form of the DR1 was prepared by removing the sixteen residue 
peptide from the peptide-binding grove. SEC3 was removed from both structures.   
  79  
The energy of the system was minimized with the steepest descent 
algorithm, followed by a 600 ps of positional restraint dynamics to generate the 
starting point for molecular dynamics.  The GROMOS9643a1 force field (Kony, 
Hunenberger et al. 2007) was used, and all simulations were carried out at 
constant temperature (298 K) , pressure (1 atm), and number of molecules using 
a Berendsen weak coupling bath with a coupling constant of 0.1 ps for 
temperature and 0.5 ps for the pressure (Berendsen 1984).  A twin range cut-off 
of 0.9/1.4 nm for van der Waals interactions was applied, and the particle mesh 
Ewald algorithm was used for long range electrostatic interactions (Essmann 
1995). Neighbor lists were utilized and updated every five steps, and all protein 
and water bond lengths were constrained using the LINCS and SETTLE 
algorithm, respectively (Hess 1997). 
The length of the simulation was determined by monitoring the 
convergence of various mechanical properties of the system.  The simulation 
was stopped when the value for the root mean square deviation (RMSD) did not 
fluctuate more than 3.0 Ǻ from its average value during 2 ns.  As described (Villa, 
Balaeff et al. 2005) if the simulation reached an RMSD that oscillates around a 
constant value, it can be assumed the system has converged to a stable or a 
metastable structure.  For both systems, the simulations were terminated after 60 
ns with a time step of 2 fs.  The coordinates were saved every five picoseconds 
and the analysis was performed using GROMACS v.3.2.1 simulation package 
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(Berdensen 1995). All molecular graphics images were generated using the 
Visual Molecular Dynamics (VMD) software (Humphrey 1996). 
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CHAPTER III 
The class II MHC 310 helix and adjacent extended strand region 
are key structural determinants that dictate HLA-DM 
susceptibility and peptide exchange 
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ABSTRACT 
HLA-DM is required for efficient peptide exchange on class II MHC 
molecules, but its mechanism of action is controversial. A recently proposed 
mechanism for HLA-DM action posits spontaneous release of peptide from the 
P1 pocket as a prerequisite for productive HLA-DM interaction.  Using a 
hydrogen-deuterium exchange technique, we show that MHC-peptide hydrogen 
bonds in the vicinity of the P1 pocket are disproportionally stable, inconsistent 
with a spontaneous release mechanism.  Instead, we observe that interaction 
with HLA-DM is driven by a conformational change of the fully peptide-bound 
MHC protein.   We trapped an intermediate state of the class II MHC-peptide 
complex by substitution of αF54, resulting in a protein with increased HLA-DM 
binding affinity, weakened MHC-peptide hydrogen bonding, and increased 
susceptibility to DM-mediated peptide exchange. Structural analysis reveals a set 
of concerted conformational alterations near the putative DM-binding interface 
that can explain these phenomena.  
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INTRODUCTION 
 HLA-DM (DM) facilitates peptide exchange on class II MHC (MHC II) 
proteins, and is required for efficient peptide loading in vivo (Morris, Shaman et 
al. 1994).  MHC II molecules assemble in the endoplasmic reticulum with the 
class II – associated invariant chain chaperone, which is subsequently cleaved 
by endosomal proteases leaving a short fragment known as CLIP bound in the 
MHC peptide binding groove (Machamer and Cresswell 1982; Blum and 
Cresswell 1988). DM facilitates the exchange of CLIP for peptides generated by 
endosomal proteolytic digestion of endogenous and exogenous proteins, 
resulting in a library of peptide antigens bound to MHC II proteins that are 
transported to the cell surface for inspection by antigen receptors on CD4+ T 
cells (Denzin and Cresswell 1995; Sloan, Cameron et al. 1995; Kropshofer, Vogt 
et al. 1996). In vitro experiments have corroborated the roles for DM as a peptide 
exchange factor (Kropshofer, Vogt et al. 1996; Vogt, Kropshofer et al. 1996; 
Weber, Evavold et al. 1996; Doebele, Busch et al. 2000) as well as a molecular 
chaperone that prevents peptide free MHC II molecules from becoming inactive 
and from forming aggregates (Denzin, Hammond et al. 1996; Kropshofer, Arndt 
et al. 1997).  
 Despite intensive investigation, details regarding the structural nature of 
how DM and MHC II interact have not been forthcoming. Although crystal 
structures have been determined for isolated MHC II proteins as well as for DM, 
there is scant evidence for the structural mechanism involved in DM facilitated 
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peptide binding and exchange. Part of the difficulty in developing a complete 
understanding of the interaction of DM and MHC II may be due to the presence 
of multiple conformers of DM (Busch, Reich et al. 1998) as well as MHC II 
(Zarutskie, Sato et al. 1999; Chou and Sadegh-Nasseri 2000; Verreck, Fargeas 
et al. 2001). At least for MHC II, the conformers believed to be involved in 
interaction with DM are thought to be kinetically unstable in that they undergo 
rapid isomerization to an inactive conformation (Zarutskie, Busch et al. 2001) and 
may not be amenable to structural analysis using conventional high-resolution 
methods such as x-ray crystallography.  Previous work using directed screens 
(Doebele, Busch et al. 2000; Pashine, Busch et al. 2003), leucine zippered 
proteins (Busch, Pashine et al. 2002), and tethered peptide approaches 
(Stratikos, Mosyak et al. 2002) has identified residues on lateral surfaces of both 
DM and MHC II that are critical for the functional interaction. However, structural 
characterization of the DM-MHC II complex, dynamic changes that occur as a 
result of the interaction, and how formation of the complex facilitates peptide 
exchange have not been described. 
 Due in part to the paucity of structural information, details regarding the 
interaction of DM with MHC II have been controversial and several models have 
been put forward. These models fall into two general mechanistic categories: one 
that suggests that DM catalyzed peptide release is mediated by disruption of the 
conserved hydrogen bond network between the peptide and the MHC II (Weber, 
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Evavold et al. 1996),and another category that suggests that the action of DM is 
more complex (Busch, Rinderknecht et al. 2005). 
  Disruption of the MHC-peptide hydrogen bond network was put forth as an 
attractive target for DM because it allows for a peptide sequence-independent 
exchange mechanism (Weber, Evavold et al. 1996). Peptides are bound by MHC 
II molecules in a canonical, extended polyproline-II conformation with conserved 
hydrogen bonds between the peptide backbone and conserved MHC II main-
chain and side-chain atoms (McFarland and Beeson 2002). In total, ~16 
hydrogen bonds are formed with the peptide backbone.  In this model category, 
DM-induced disruption of one or more critical hydrogen bonds results in 
catalyzed peptide exchange (McFarland, Katz et al. 2001; Stratikos, Wiley et al. 
2004; Narayan, Chou et al. 2007). However, mutagenesis of the MHC II side 
chains involved in this interaction has shown for the most part that disruption of 
individual H-bonds do not diminish DM catalysis. One study proposed that the 
βH81 H-bond was responsible for the entire mode of DM catalysis (Narayan, 
Chou et al. 2007), however two other groups have found that this as well as other 
point mutations do not prevent the effect of DM (Ferrante and Gorski ; Zhou, 
Callaway et al. 2009). In addition, disruption of this H-bond network by either 
truncation or methylation of the peptide has revealed that augmentation of DM-
mediated peptide catalysis occurs when the N-terminal peptide H-bonds are 
disrupted (Stratikos, Wiley et al. 2004). These studies show that while disruption 
of the H-bond network can augment DM-mediated peptide release, the 
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relationship between the hydrogen bond network and the actual catalytic 
mechanism of DM remains unknown.  
 Models that put forth a more complex mechanism for DM catalysis include 
roles for conformational heterogeneity (Sadegh-Nasseri, Natarajan et al. 2010) 
(Anders, Call et al. 2011), and the involvement of the peptide side chains in 
addition to the cooperativity of the H-bond network in regards to DM function 
(Belmares, Busch et al. 2002).  The MHC II P1 side-chain binding pocket, a 
major determinant for the peptide-MHC interaction(Sato, Zarutskie et al. 2000), 
has been investigated as a target for DM action. One study suggests that DM 
recognizes a flexible conformation of MHC II with alterations of the P1 pocket 
relative to the canonically “rigid” crystal structures to date (Chou and Sadegh-
Nasseri 2000), while another recent study has suggested that the occupancy of 
the P1 pocket may be a critical determinant for DM susceptibility (Anders, Call et 
al. 2011).  In the latter study, spontaneous release of the peptide from the P1 
pocket, was put forth as prerequisite to DM interaction. In contrast to a model 
that focus on interactions in the P1 pocket, a study of many MHC II and peptide 
variants suggests that interactions along the entire peptide binding groove 
contribute to the susceptibility of DM (Belmares, Busch et al. 2002).  In addition, 
it has also been suggested that DM functions by reducing the cooperativity of 
peptide side chain interactions along the length of the peptide, while mediating 
peptide exchange by way of a “push-off” mechanism (Ferrante, Anderson et al. 
2008).  
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 In this work, we describe a structural and dynamic framework for how 
conformational heterogeneity of MHC II may influence DM susceptibility. We 
used a novel mass-spectrometry approach to establish the relative strength of 
the individual hydrogen bonds along the backbone of MHC II- bound peptide. 
Through targeted mutagenesis of MHC II residues in the vicinity of the peptide N-
terminus and P1 pocket, we identified a point substitution that leads to alterations 
within the hydrogen bonding network, increased susceptibility to DM mediated 
peptide exchange , and greatly increased DM binding affinity.  Structural 
characterization of the protein revealed an altered MHC II conformation in a 
molecule contacted at the presumptive DM interaction site, with alterations in the 
alpha subunit 310 helical region (α45-50) and flanking extended strand region 
(α51-54). These changes appear to be key structural determinants for DM 
interaction and peptide exchange.  
 
RESULTS 
Measurement of MHC-peptide hydrogen bond strengths using hydrogen-
deuterium exchange mass spectrometry 
The MHC II-peptide hydrogen bonds are believed to be of fundamental 
importance to the MHC II-peptide interaction (McFarland, Beeson et al. 1999; 
McFarland, Katz et al. 2001; Bandyopadhyay, Arneson et al. 2008), but their role 
in DM-mediated catalysis has been controversial (Belmares, Busch et al. 2002) 
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(Ferrante and Gorski ; Narayan, Chou et al. 2007; Zhou, Callaway et al. 
2009),(Vogt, Kropshofer et al. 1997), in part because of a lack of methods to 
examine the strength of these bonds directly. We devised an experimental 
protocol that uses amide hydrogen-deuterium exchange (H/Dx) and mass 
spectrometry to examine the strengths of the MHC II-peptide hydrogen bonds in 
native, unlabeled, soluble MHC II-peptide complexes.  Amide hydrogens 
exchange with solvent on an experimentally useful time scale of milliseconds to 
hours, with the exchange rate depending on the strength of the amide hydrogen 
bond (Marcsisin and Engen). Analysis of amide H/D exchange rates by mass 
spectrometry has been useful in studies of protein folding and structure, but can 
be limited by the need to fragment large proteins into peptides sufficiently small 
for high-resolution mass analysis (Tsutsui and Wintrode 2007). Here, we were 
able to strip the peptide from the MHC II under conditions that minimize further 
exchange, so that conventional high-resolution LTQ HPLC/MS could be used to 
evaluate H/Dx in MHC II-peptide amide bonds by direct examination of the 
released peptide, which retained the pattern of deuterium incorporation obtained 
as a result of amide protection by MHC II binding.  
The experiment is diagrammed in Figure 3.1a.  Preformed complexes of 
HLA-DR1 and influenza-derived HA peptide (MHC II-pep) in aqueous solution 
were transferred to a D2O solution, inducing exchange between macromolecular 
amide hydrogens and solvent deuterons.  At various times the reaction was 
quenched by transfer to ice-cold pH 2.7 buffer, which removes the peptide from 
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the MHC, while preserving the pattern of amide H/D present in the MHC-peptide 
complex.  Peptide was separated from MHC II by in-line C4 and C18 reverse-
phase microcolumns, and peptide mass measured by high-resolution mass  
FIGURE 3.1 
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Figure 3.1. Hydrogen-Deuterium exchange mass spectroscopy to evaluate 
MHC II-peptide hydrogen bonding strengths. (a) Schematic showing 
experimental design. WT was pre-loaded with HA peptide, then diluted into D2O 
for variable lengths of time. The reaction was quenched by dilution into ice cold 
glycine buffer pH 2.7, which also releases peptide from the MHC II. Sample was 
then injected onto an on-line series of columns, with the MHC II retained by the 
C4 column and the HA is retained on and chromatographically eluted from the 
C18 column into the electrospray ion source of a Thermo LTQ ion trap mass 
spectrometer for mass analysis. (b) Mass spectra of free and MHCII-bound HA 
peptide . Left panel, mass spectrum of the HA peptide showing the expected 
isotopic distribution for the [M+2H]2+ ion of the unlabeled peptide. The weighted 
intensities of the ion masses are averaged to obtain the average mass of the 
peptide. Center panel, mass spectrum of the HA peptide after equilibration in 
D2O. Right panel, mass spectrum of HA peptide eluted from MHC II-complex 
after 30 second incubation in D2O, showing MHC-mediated protection from H-D 
exchange at most of the peptide amide positions. (c) Average mass of the HA 
peptide eluted from MHC II complex for various times of incubation in D2O. Data 
were fit to a two phase exponential association model. (d) Peptide dissociation 
assays were performed by measuring the decay of polarization for Alexa-488 
labeled HA peptide from pre-bound complex.  
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spectrometry.   The distribution of stable isotopes gives a series of peaks in the 
MS spectra (Fig. 3.1b). For the free HA peptide in H2O solution, the average 
mass (1503.8) and the ion distribution pattern (Fig. 3.1b, left) correspond with 
that expected for the HA peptide sequence and the known hydrogen, carbon, 
nitrogen, and oxygen isotope abundances (Fig. 3.2). For the free HA peptide 
transferred to 90% D2O solution, the average mass increases to 1511.9, with 
corresponding changes in the mass spectrum (Fig. 3.1b, center).  The average 
mass change, +8.1 Da, corresponds to addition of 12 D, after accounting for 
back-exchange during the analysis (Fig. 3.2), and consistent with the twelve 
amide bonds present in the 13-mer HA peptide. For the MHC II-HA complex 
immediately after transfer to 90% D2O, the average mass is 1504.6 (Fig. 3.1b, 
right). Thus, interaction with the MHC II protein protects ~90% of the peptide 
amide from exchange.  
With increasing time in D2O, additional H/D exchange is observed, with 
multiphasic kinetics (Fig. 3.1c).  The time dependent H/D exchange kinetic is fit 
well by a two-phase exponential rise equation that describes an unresolved initial 
phase (t1/2 < 1min), a fast phase with half-time of a few minutes, and a much 
longer slow phase, with a half-time of ~18hr (Table 3.1). The slow phase is still 
substantially faster than the rate of peptide release (Fig. 3.1d).  Overall this 
analysis reveals that the bound peptide’s amide NH bonds exchange at 
dramatically different rates.  
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FIGURE 3.2 
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FIGURE 3.2. HDx Back-exchange fitting. Hydrogen-deuterium exchange 
isotope distribution pattern in 90% D2O. Closed bars, observed isotope 
distribution, open bars, calculated isotope distribution with 28% back exchange  
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We were able to assign several individual peptide amides to particular 
kinetic phases using multidimensional electron transfer dissocation (ETD) mass 
spectrometry.  ETD is an ion fragmentation method that can be used inside the 
mass spectometer to produce peptide fragments for MS/MS sequence analysis 
(Mikesh, Ueberheide et al. 2006). Peptides are fragmented between NH and Cα 
atoms (Fig 3.3a) producing sets of c-series and z-series ions (Fig 3.3b), 
analogous to the b-series and y-series of conventional collison-induced 
dissociation (CID) (Mikesh, Ueberheide et al. 2006).  Unlike CID, however, ETD 
does not result in H/D scrambling (Zehl, Rand et al. 2008), so that the ion 
fragments retain the pattern of deuterium incorporation present in the eluted 
peptides.  Thus, different peptide fragments exhibit different kinetics of deuterium 
incorporation, depending on the protection from D2O exchange for the particular 
amide NH atoms present in that fragment.  For example the c3 fragment has very 
little deuterium incorporation even at 512 minutes, whereas the c6 fragment is 
substantially exchanged by 2 min (Fig 3.3c).  We were able to measure 
deuterium incorporation rates for 6 c-series ions (c2,c3,c5,c6,c8,c9) and seven z-
series ions (z4,z5,z7,z9,z10.z11,z12), although with weaker signals for the z-
series (complete analysis in Table 3.2).  By subtracting the mass differences 
(ΔMW) for adjacent c-series (or z-series) ions, the contributions of particular 
peptide NH atoms (or pairs of NH atoms) can be obtained.  Figure 3.3d shows 
such a ΔΔMW analysis, with the extracted H/D exchange of each peptide NH  
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FIGURE 3.3 
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FIGURE 3.3. HDx mapping by ETD of HA peptide. 
(a) Schematic representing the N to C-terminus of a peptide backbone. Dashed 
lines with opposing arrows represent potential ion series that are possible upon  
backbone cleavage by different methods. Fragmentation by ETD produces c and 
z ions. (b) Cartoon representation of peptide binding groove with backbone of HA 
shown in stick. Letters indicate the residue at each position along the backbone. 
Dashed lines represent amides that are protected by bonding to the MHC II 
through direct hydrogen bonding or through ordered solvent. Hydrogen bonding 
partners on the MHC II are indicated in stick. c and z fragmentation pattern is 
shown by opposing arrows as in (a). (c) Representative data for the HA  C3 ion 
(left) and the C6 ion (right) with no deuterium incorporation (H2O), with deuterium 
incorporation at various time points (2, 218 and 512 minutes) while bound to the 
MHC II, and for the fully unprotected HA (D2O). (d) Deuterium incorporation for 
each amine group along the peptide backbone for different times of incubation in 
D2O. The Y axis represents the change in molecular weight for the unexchanged 
ion (ΔMW), which is then subtracted between sequential ion fragments in order to 
obtain the amount of deuterium incorporation of each amide at that time point 
(ΔΔMW). Black bars represent the fully exchanged ion fragment in D2O, and the 
open bars represent an increase in time, with triangles representing 2, 218 and 
512minutes. The c-series sequential ions and the corresponding amine group are 
indicted below 
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atom (or pairs of NH atoms) at various times shown in open bars and the fully 
exchanged mass difference shown in black bars.  Corresponding z-series data 
are shown in Fig. 3.4a with an overall summary of both c-series and z-series data 
in Fig. 3.5.  It is readily apparent that the Y3 and V4 positions are the most 
strongly protected of all the peptide NH, indicating that these participate in the 
strongest hydrogen bonding interactions with the lowest spontaneous exposure 
rate.  These positions flank the P1 side chain binding pocket. Thus it would be 
highly unlikely for the P1 side chain to spontaneously escape the P1 pocket, and 
so we sought other explanations for the key role of this region in DM-mediated 
peptide exchange catalysis. 
 
Substitution of αF54 dramatically increases susceptibility of MHC II to DM-
catalyzed peptide dissociation  
To determine the relevance of the region proximal to the P1 pocket for DM 
catalyzed peptide dissociation, we engineered mutations in the extended strand 
region of the alpha subunit at residues αF51, αS53, and αF54 (Fig 3.6a, Table 
3.3), and at residues surrounding the P1 pocket  αL45, αF48, βF89, and βW153 
(Fig 3.7, Table 3.3),  As a control, we also mutated αQ57, located on the alpha 
subunit helix one turn beyond the extended strand region.  Recombinant proteins 
carrying the mutations were expressed in E. coli and refolded in vitro using 
standard methods (Frayser, Sato et al. 1999).  Each of the proteins bound to the  
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FIGURE 3.4 
  101  
FIGURE 3.4. ETD ΔΔMW for the z ion series; Change in molecular weight 
plotted for each amine group along the peptide backbone. The y-axis represents 
the change in molecular weight of the deuterated ion from the unexchanged ion 
which is then subtracted between ion fragments in order to obtain the amount of 
deuterium incorporated at each amide. Top panel shows z series calculations for 
the HA alone or in complex with WT MHC II, bottom panel shows HA alone or in 
complex with F54C MHC II. Black bars represent the fully exchanged ion 
fragment in D2O, and the open bars represent the time course in which the MHC 
II HA complex was incubated in deuterium. Determination of the incremental 
mass incorporated for each amine was calculated as the ΔΔMW; the deuterium 
incorporation for each ion was calculated as the difference in mass between the 
deuterated ion and it’s corresponding ion in H2O (ΔMW), these differences were 
then subtracted for neighboring ions in order to obtain the incremental mass 
increases for each amine along the backbone. The subtracted ion species are 
indicated and the amine group which corresponds to the fragment is indicated 
below in parenthesis. 
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FIGURE 3.5 
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FIGURE 3.5. Summary of HDx data for HA peptide NH bonds in complex 
with WT and F54C HLA-DR1.  
The HA peptide sequence is shown with amide NH groups involved in hydrogen 
bonding interactions depicted by dashed lines. Individual NH or groups of NH 
atoms were characterized as having slow, medium, fast, or unprotected (very 
fast) HDx based on comparison of ΔΔMW values to corresponding values 
unbound peptide as follows: slow is <30% exchanged at all time points; medium 
is < 80% exchanged at 2min and 128 min (usually at all time points); fast is < 
80% at 2 min, but > 80% exchanged at later points; unprotected is >80% 
exchanged at 2 min (and usually at all time points) 
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FIGURE 3.6 
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FIGURE 3.6.  Substitution of αF54 results in a dramatic increase in the rate 
of DM catalyzed peptide exchange. (a) Schematic representation of the 
peptide binding groove of MHC II with mutated residues shown in blue. (b-g) 
Peptide release assays performed by monitoring decay of Alexa 488-CLIP 
polarization signal in the presence of unlabeled peptide and various 
concentrations of DM. (h) The kobs values for each exponential decay were 
plotted against the concentration of DM. Inset with expanded y-axis to show the 
slopes for WT, αQ57C and αS53A. (i) DM-mediated rate enhancements were 
calculated for each mutant by dividing the slope of the kobs vs. [DM] plots by the 
intrinsic dissociation rates. Closed bars, data for MHC II-CLIP.  Open bars, data 
for MHC II-HA.  (i) The kobs values for the exponential decay in the HA peptide 
dissociation assays were plotted against the concentration of DM with complexes 
labeled on the graph.
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FIGURE 3.7 
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FIGURE 3.7. Mutation of other residues around the P1 pocket does not alter 
the effect of HLA-DM on peptide release. (a) Cartoon diagram of N-terminal 
region of the peptide binding groove. Residues mutated to alanines are 
represented in blue stick. (b-e) Dissociation of Alexa-488 labeled CLIP peptide 
from αF548A (b), bW153A (c), αL45A(d)  and βF89A (e) show similar patterns of 
release. (f-i) SPR analysis shows that no binding is detected for any of these 
point mutations when 2.5 µM DM is injected in the mobile phase. 
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TABLE 3.3 MHC-peptide binding parameters 
MHCII t112, intrinslca koff ,intrinsicD OM Rate 
hrs (9S% C;I.) "10~'min-1 (SO) 
koff , interceptC 
*10~'min- susceptibility d enhancement e 
"10~min-1IlM-1 IlM-1 (SO) 
(SOl 
WT 19.0 (17.1-21.S) 0.6 (0.1) 0.67 (0.04) 2.8 (0.3) 4.6 (1.0) 
aQS7C 24.7 (20.S-31.0) O.S (0.1) 0.S7 (0,01 ) 1.3 (O.S) 2.8 (1.2) 
aFS4C 2.0 (1.8-2.2) 5.7 (0.4) 8.6 (4.3) 847 (94) 149 (20) 
aF54A 4.5 (4.24.8) 2.6 (0.2) 1.7 (2.1) 10S7 (226) 407 (95) 
aSS3A 36.6 (33.9-40.0) 0.31 (0~03) 1.S (0.7) 22.9 (5.1) 73.9 (17.9) 
aFS1A 19.8 (17,7-22.4) 0.6 (O.OS) none none none 
aF48A 10.0 (7.9-13.6) 1,2 (0.2) 0.9 (0 .. 1) 7.3 . (0.9) 6.1 (1.3) 
aL4SA 10.1 (8.8-11.7) 1.1 (0.2) 1.1 (0.1) 10.5 (0.7) 9.S (1.8) 
~F89A 4.0 (2.6-8.1) 2.9 (0.7) 3.0 (4.0) 19.6 (2.9) 6.8(1.8) 
~W153A 6.8 {6.2-7.4} 1.7 {0.2} . 1.8 (0.1) . 6.0 (1.2} 3.5 (o.a} 
WT' 1988.0 0.0058 0.00S9 0.006 1.0 (0.1) 
(1889-2098) (0.0003) (0.0001) (O.OOS) 
aFS4Cf 31.9 0.362 0.41 42.7S 118 
(28.8-3S.7} (0.042} . (O.O?) {0.01} {20} 
a Measured for a MHC II-peptide dissociation reaction performed in the absence 
of OM. Values in parentheses represent the 95% confidence interval for 3 or 
more replicates. 
b Intrinsic dissociation rate, kott. Values in parentheses represent the standard 
deviation ·of 3-6 replicates. 
C V-intercept extrapolated from linear regression of the !<off vs [OM]. plot. Values in 
. , 
parentheses represent uncertainty from the linear fit. 
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could be loaded with peptide using a standard protocol. We monitored the 
intrinsic rate of peptide dissociation from the mutant proteins using Alexa488-
labeled CLIP peptide in a fluorescence polarization assay (Fig 3.6b-g, triangles, 
Fig 3.7).  Dissociation time courses fit well to single exponential decays, with t1/2 
and koff values shown in Table 3.3.  The mutations had varying effects, ranging 
from a 9.5-fold increase in dissociation rate for αF54C to a 1.9-fold decrease for 
αS53A. 
We tested the susceptibility of the MHC II mutant proteins to DM in a 
functional assay, where increasing concentrations of DM resulted in an increased 
rate of peptide dissociation (Fig 3.6b-g). In the range tested, peptide dissociation 
rate constants increased linearly with increasing DM concentration for each of 
the mutant proteins (Fig 3.6h, Fig. 3.8), with the slope reflecting the susceptibility 
of each mutant protein to DM-mediated peptide dissociation. The DM-
susceptibility of the control mutant αQ57C (Fig. 3.6f) was similar to WT (Fig 
3.6b). Substituting αF51 by alanine resulted in a protein that was resistant to DM 
(Fig 3.6e).  Other mutations at this position in the context of another MHC II 
previously have been shown to block DM-mediated peptide dissociation 
(Doebele, Busch et al. 2000).  Mutation of residue αS53 to alanine increased the 
susceptibility to DM, with αS53A approximately seven-fold more sensitive to DM 
than WT (Fig 3.6c).   
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FIGURE 3.8 
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FIGURE 3.8.  Effect of DM on peptide dissociation rates for point mutants. 
Each plot shows the Linear regression of Kobs vs [DM]. The DM enhancement 
factor was calculated by dividing slope of the linear dependence on DM by the 
intrinsic peptide dissociation rate for each of the mutants.  
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In contrast, large effects on susceptibility to DM were observed upon substitution 
of αF54.  Both αF54C and αF54A were exquisitely sensitive to DM, with 
concentrations as low as 25nM DM inducing large increases in peptide 
dissociation rates (Fig 3.6d,g).  Values for the slopes of the DM-dependent rate 
profiles, i.e. the DM susceptibility, were 302 and 378 times greater for αF54C and 
αF54A, respectively, as compared to WT (Fig 3.6h, Table 3.3).   
 Previous studies have used the slope of the DM susceptibility curve 
divided by the intrinsic dissociation rate constant, i.e. the fold-enhancement in 
peptide release per unit of DM or the specific rate enhancement, as a measure of 
DM’s catalytic efficacy towards a particular substrate (Weber, Evavold et al. 
1996; Stratikos, Wiley et al. 2004).  Even after this normalization, the αF54 
mutations still are extreme outliers, with specific rate enhancement over 400 µM-1 
for αF54A, almost 90-times greater than for WT (Fig 3.6i, Table 3.3). Similar 
values were obtained regardless of whether intrinsic dissociation rates were 
determined by experiments performed in the absence of DM or by extrapolation 
of DM-dependent rate profiles (Table 3.3).  The extreme sensitivity of αF54C to 
DM was not restricted to the CLIP peptide, as it was also observed for the HA 
peptide (Fig 3.6i, open bars, Fig 3.6j, Fig. 3.9). 
 These results indicate that substitution of αF54 does not substantially 
impair MHC II-peptide interactions, but does make the MHC II protein particularly 
susceptible to DM-mediated peptide release. 
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FIGURE 3.9 
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FIGURE 3.9. Kinetics of HA peptide release from WT and αF54C MHC II. 
Peptide release assays performed by monitoring decay of polarization signal in 
the presence of unlabeled peptide with or without a dilution series of DM. 
Concentrations of DM are color and symbol coded. The linear dependence on 
DM for peptide release was plotted as Kobs against the concentration of DM. 
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Substitution of αF54 weaken MHC-peptide hydrogen bonding interactions 
In previous work, it was shown that disruption of key hydrogen bonds in 
the vicinity of the P1 pocket by chemical modification led to augmented DM 
susceptibility (Stratikos, Wiley et al. 2004). Coupled with our observation that the 
αF54C mutation greatly increased DM susceptibility, we hypothesized that this 
substitution altered the peptide-MHC II hydrogen bond network. We determined 
the effect of the αF54C mutation on the overall hydrogen bond network and 
mapped changes to individual hydrogen bonds using the HDx/MS/MS approach 
outline above for the WT-HA complex. The amplitudes of the unresolved initial 
H/D-exchange phases are the same for both WT and αF54C (Fig 3.10 b). The 
fast phase amplitudes also are similar for WT and αF54C, as are the respective 
half-lives for this phase (Table 3.1). However, the slow phase of HDx  is 
significantly different for αF54C and WT with half-lives of 1.8 and 18.1 hrs, 
respectively (Table 3.1).  The enhanced rate of hydrogen exchange into the 
bound peptide for αF54C indicates weakened MHC II-peptide hydrogen bonding 
and increased structural dynamics leading to increased exposure of several 
peptide amide NH groups. 
In order to resolve the particular amide NH groups involved in each phase, 
we employed ETD/MS/MS as outlined above for the WT-HA complex. Overall the 
pattern of deuterium incorporation is similar for αF54C as for the WT-HA complex 
(Fig. 3.10c), however, the relative strengths of the Y3 and V4 hydrogen bonds,  
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FIGURE 3.10 
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FIGURE 3.10. Mutation of αF54 alters the H-bonding properties between the 
MHC II and peptide. (a) Cartoon representation of the peptide binding groove 
with αF54 shown in stick, in addition to other conserved MHC II residues that 
participate in the H-bond network to the peptide backbone. The P1 tyrosine side 
chain is shown as spheres. (b) Hydrogen deuterium exchange assay (top) 
Average mass for HA peptide was determined at various time points as a fraction 
of total deuterium incorporation for free HA. HA bound to αF54C is shown as a 
solid line and that bound to WT is dotted. Both sets of data were fit to a two 
phase exponential association model. (d) Peptide dissociation assays were 
performed by measuring the decay of polarization fro alexa-488 labeled HA 
peptide from pre-bound complex. (c) Deuterium incorporation for each amine 
group along the peptide backbone for different times of incubation in D2O. The Y 
axis represents the change in molecular weight for the unexchanged ion (ΔMW), 
which is then subtracted between sequential ion fragments in order to obtain the 
amount of deuterium incorporation of each amide at that time point (ΔΔMW). 
Black bars represent the fully exchanged ion fragment in D2O, and the open bars 
represent an increase in time, with triangles representing 2, 218 and 512minutes. 
The c-series sequential ions and the corresponding amine group are indicted 
below 
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which are on either side of the alpha 54 position (Fig. 3.10a), exchange faster 
than for the WT-HA complex (Fig. 3.10c; Fig 3.11) For the WT-HA complex, 
these hydrogen bonds represent the most stable of the interactions, and would 
be expected to correspond to those most important in determining the overall 
peptide-MHC lifetime. Our results suggest that the αF54C mutation disrupts 
these key hydrogen bonds in the N-terminal region of the peptide binding groove.  
 
Substitution of αF54 dramatically increases binding to DM  
We hypothesized that the disruption of the hydrogen bond network by the 
αF54C substitution and its greater DM susceptibility would be accompanied by 
increased MHC II-DM binding affinity. We tested this idea using surface plasmon 
resonance.  Because the physiological MHC II-DM interaction occurs at low pH in 
endosomal / lysosomal compartments, we performed binding experiments at pH 
5.6.   We immobilized peptide-free WT and each of the mutants, and measured 
the binding of various concentrations of DM (Fig. 3.12). Specific, saturable, dose-
dependent binding was detected for both αF54 variants (Fig. 3.12b,c), but not for 
WT (Fig. 3.12a) αS53A (Fig. 3.12e), αQ57C (Fig. 3.12d), or αF51A (Fig. 3.12f).  
Equilibrium binding analysis revealed Kd,app values of 0.5 µM and 0.7 µM for 
αF54A and αF54C, respectively (Fig. 3.12g). 
We performed several experiments to verify the specificity of the tight 
binding observed for αF54A and αF54C to DM.  First, we observed substantially  
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FIGURE 3.11 
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FIGURE 3.11. αF54C ETD representative data. Representative ETD data for 
HA alone in H2O, D2O or in various states of protection by the αF54C MHC II. 
The C3 (left) and the C6 (right) ion series are shown.  
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FIGURE 3.12. SPR analysis of αF54C/αF54A binding to DM. (a-f) Various 
concentrations of DM were flowed over immobilized WT and mutant MHC II. Only 
the 2.5 µM DM concentration is shown for αQ57C, αS53A, and αF51A. At the 
concentrations tested, binding was observed only for αF54C and αF54A. (g) 
Equilibrium analysis of values obtained from DM binding to immobilized αF54C, 
circles, and αF54A, triangles, with Scatchard plot shown as inset. .(h,i) 10uM DM 
was injected over immobilized αF54C (h) or WT (i) at pH 7.0, solid line, or at pH 
5.6, dotted line. Binding for αF54C was greatly reduced at higher pH and no 
binding was detected for WT at either pH tested. (j) Blocking experiment showing 
DM (5 µM) binding to immobilized αF54C-CLIP (left panel), followed by anti-MHC 
antibody LB3.1 (center) and subsequent diminishment of DM (5 µM) binding. (k,l) 
Equilibrium analysis of αF54C-CLIP (k) or WT-CLIP(l) binding to immobilized 
DM.  (m) Equilibrium analysis of values obtained from αF54C binding to 
immobilized DM, with Scatchard plot shown as inset.  
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reduced binding of DM to immobilized αF54C at pH 7.0 relative to pH 5.6 (Fig. 
3.12h), consistent with known pH dependence of the interaction (Ullrich, Doring 
et al. 1997).  We did not observe binding of DM to WT at either pH (Fig 3.12i) 
Second, binding was abrogated by preincubation with a monoclonal antibody 
(LB3.1) specific for a conformational epitope on MHC II (Fu and Karr 1994) near 
the presumptive DM binding interface (Doebele, Busch et al. 2000) (Fig 3.12j).  
Finally, DM binding was observed also for CLIP peptide complexes of αF54C but 
not WT (Fig. 3.12k,l,m). 
These results indicate that αF54 substitutions, which increase sensitivity 
to DM-mediated peptide release, also increase the binding affinity for DM.   
 
The crystal structure of αF54C-CLIP shows a conformational change in the 
vicinity of a critical DM contact residue. 
  To investigate the structural basis for the altered hydrogen bond strengths, 
the increased DM susceptibility and the increased DM binding activity of αF54C 
in, we determined its 2.3 Å crystal structure in complex with the CLIP peptide 
(Table 3.4). For comparison, we also determined the 2.7 Å crystal structure of 
WT bound to CLIP, using crystals that were obtained from streak seeding with 
αF54C crystals. In this way, we were able to obtain a nearly isomorphous data 
set for WT-CLIP in the same unit cell as αF54C-CLIP. Previously determined 
crystal structures for WT-CLIP differed in unit cell and crystal packing 
TABLE 3.4. Data collection and refinement statistics (molecular 
replacement) 
F54C CLIP WT CLIP 
Data collection 
Space group P212121 P212121 
Cell dimensions, a, b, C 65.001, 94.870, 154.090 65.290, 95.840, 151.629 
Resolution (A) 50.0 - 2.3 (2.38-2.30)* 50 - 2.7 (2 .75-2.70) * 
Rmerge 6.9 (41.0) 12.5 (40.2) 
" sl 31.6 (4.8) 19.8 (4.1) 
Completeness (%) 100 (100) 99,9 (99.5) 
Redundancy 7.4 (7.5) 7.0 (6.8) 
Refinement 
Resolution (A) 44.0 - 2.3 (2.38-2.30) 38.6 - 2.7 (2.75-2.70) 
No. unique reflections 43,063 26,411 
Rwor1< 1 R free 18.9/22.1 19.3/23.5 
No. atoms 6751 6419 
Protein 6374 6253 
Water 487 166 
Main Chain a-factors 
ab {moI1) 16 28 
peptide (moI1) 16 33 
ab (moI2) 22 27 
peptide (moI2) 32 34 
Waters 20 23 
R.M.S.D. 
Bond lengths (A) 0.004 0.002 
Bond angles (0) 0.82 0.63 
R.M.S.D. NCS 
a1 b1 pep domain 0.62 0.46 
a2domain 0.56 0.32 
b2 domain . 0.31 0.21 
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 (Gunther, Schlundt et al.). For the structures reported here, both WT and αF54C 
crystal structures have 2 molecules in the asymmetric unit. For the WT-CLIP 
structure, both molecules (blue and green in Fig. 3.13a-e) overlay with no major 
deviations in RMSD except for an exposed loop near βP108 that shows large 
RMSD deviations between most MHC II structures solved to date. Overall the 
structure of αF54C (purple and red in Fig. 3.13a-e) was very similar to WT, 
except for a region proximal to the αF54C mutation (indicated by carets in Fig. 
3.13b,f), for which large differences were observed specifically in one of the two 
molecules in the asymmetric unit (Fig. 3.13f-i).  Residues in an altered 
conformation include the region around αM36, in the loop between two strands of 
the beta sheet platform that forms the floor of the peptide binding site, the short 
310 helix encompassing residues αL45 to αF50 at the edge of the binding site, 
and the extended stand region, αF51-αF54C. 
The conformational changes involving the αL45 to αF51 region of 
molecule 2 of αF54C can be seen in the ribbon diagrams shown in Figure 3.14a-
c.  The conformational change results in a ~20º reorientation of the short 310 
helix, together with a partial unwinding towards a more canonical alpha-helical 
pitch (compare Fig. 3.14b,c). These changes are accompanied by a concerted 
set of rotamer changes in residues that surround the P1 pocket.   In addition to a 
reorientation of the αF51 residue, a large change is observed for αF48, which  
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FIGURE 3.13
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FIGURE 3.13.  An altered conformation of the 310 helix and adjacent strand 
region for one molecule in the asymmetric unit of the αF54C 
structure.  (a-e) Structure alignment of C-alpha traces of WT and αF54C, with 
molecules 1 and 2 of WT in blue and green, and molecules 1 and 2 of αF54C in 
purple and red. (a) Alignment of entire protein for all of the molecules. (b-e) 
Individual domain alignments for all of the molecules, (b) The α36-α54 region of 
αF54C shows a deviation from the other molecules when the alpha 1 domains 
are aligned.  (c-e) The β1 and α2 domains do not show any significant deviations 
between WT and αF54C, although the β2 shows deviations around the βP108 
position. Carets indicate residues that undergo significant deviations. (f-i) Main 
chain RMSD values after alignment of the individual domains comparing the WT 
to the αF54C; black, Mol1 of WT is aligned with Mol 1 of the αF54C, red, Mol2 of 
the WT structure is aligned with Mol2 of the αF54C structure. Carets indicate 
residues with the largest RSMD between WT and αF54C.  The βP108 region is a 
partially disordered loop and shows deviations in both WT and αF54C.  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FIGURE 3.14 
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FIGURE 3.14.  X-ray crystal structures of WT and αF54C bound to the CLIP 
peptide.  (a) Top panel, ribbon diagram of WT peptide binding groove with CLIP 
peptide shown in yellow. The peptide M91 side chain which occupies the P1 
pocket is shown in dots, top view.  Bottom panel, 90° rotation showing the end-on 
view of the WT structure. Boxes indicate regions expanded in (b-c). (b) Top 
panel,  overlay of WT mol1 (blue), WT mol2 (purple) and αF54C mol1 (green) 
with M91 side chain shown in dots, residues αF48, αF51 and β89 shown in 
sticks. Bottom panel, 90° rotation showing this region with the additional residues 
αL45 and βW153. Dotted line represents helical axis. (c) αF54C mol2 (red) 
shown with the same alignment as molecules in panel (b). (d) Surface 
representation of the P1 pockets for (a) WT mol1 (blue) WT mol2 (green) αF54C 
mol1 (purple) αF54C mol2 (red) with calculated surface area shown below the 
methionine residue engaged in the P1 pocket.  Changes in the P1 pocket are 
mediated primarily by the rearrangement of residues αF48 and βF89, which are 
shown in sticks.
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positions its side chain on the side of the P1 pocket, displacing βF89 which also 
undergoes a rotamer change placing it more distal from the P1 pocket. The 
largest change is seen at αL45, which moves to contact with the βW153, 
replacing the contact normally made by the αF48 side chain. The 
rearrangements of αL45, αF48, and βF89 resulted in changes in the shape and 
volume of the P1 pocket (Figure 3.14d).   
The conformational changes in the 310 helix and adjacent strand region 
appear to be due to a crystal contact at the αF51 position in molecule 2 of the 
asymmetric unit (Fig. 3.15). The contact is observed for both WT (Fig. 3.15a) and 
αF54C (Fig. 3.15b), but only in the mutant is the conformational change induced. 
These changes result in lowered B-factors for the 310 helix and adjacent strand 
region relative to the remainder of the α1β1 peptide-binding domain (Fig. 3.16).  
However, B-factors for the bound peptide increase as a result of the 
conformational change (Fig 3.16). The αF51 position is known to be critical 
determinant for DM binding and activity (Doebele, Busch et al. 2000), and 
contact with another molecule at the αF51 position may simulate the effect of a 
contact at this position with DM, thus providing a model where changes resulting 
in weaker MHC-peptide interactions may lead to peptide release.  
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FIGURE 3.15 
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FIGURE 3.15. Conformational change in αF54C Mol2 is induced by a crystal 
contact at αF51, whereas a similar contact in WT has no effect. (a) 2|Fo-Fc| 
omit electron density (blue) contoured at 1σ and stick representation model 
(blue) for WT mol2. A crystal contact at the αF51 residue is made by a residue 
(P108) from the β2 domain of another molecule in the crystal, shown with grey 
density and pink model in stick representation. The αF54 position is noted. (b) 
Density (blue) and model (red) for the F54C mol2, contoured as in panel (a). The 
αC54 position is noted. The blue model for WT is shown aligned to the αF54C 
mol2 structure.  
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FIGURE 3.16 
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FIGURE 3.16   Crystal contact induced stabilization of αF54C Mol2 but not 
WT Mol2 (a-d) B-factor putty representation, with red representing regions with 
highest B-factors and blue showing regions with lowest B-factors,  shown for both 
molecules in the αF54C structure (a-b) and the WT structure (c-d), boxed region 
is shown enlarged. The average main chain B-factors for residues α45-56, the 
α1β1 domain and the peptide are shown for each molecule. The crystal contact 
at αF51 is depicted by a black star for αF54C mol2 (b) and WT Mol2 (d).  
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DISCUSSION 
Substitution of αF54 in the MHC II extended strand region of the peptide 
binding site results in a protein with greatly increased susceptibility to DM-
mediated peptide release, increased DM-binding affinity, and increased MHC-
peptide dynamics.  The crystal structure of the αF54C mutant is very similar to 
that of the WT protein, with the exception of a set of conformational alterations 
near the N-terminus of the bound peptide involving the reorientation of the (α45-
50 ) 310 helical region, the (α41-54) adjacent extended strand as well as changes 
in the (α39-44) region; adoption of the altered conformation is dependent on 
contact of αF51, a known DM-MHC II contact site (Doebele, Busch et al. 2000). 
The increased DM binding and susceptibility to DM-mediated peptide release 
observed for the αF54C/αF54A mutations are likely to be due to conformational 
alterations induced proximally as a result of loosening the interaction between 
the extended strand and the rest of the MHC-peptide complex, as opposed to 
direct interaction with the α54 residue, which is buried in both conformations and 
also in the wild-type protein. These observations suggest that this mutation 
allows the MHC II to adopt a DM-receptive conformation.  
Several factors indicate that the conformation observed in the αF54C 
mutant can be adopted by WT and is relevant to DM-mediated peptide 
exchange.  Modeling studies of MHC II suggest that the N-terminal side of the 
peptide binding site undergoes conformational alteration concurrent with peptide 
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release (Nojima, Takeda-Shitaka et al. 2003; Gupta, Hopner et al. 2008; Painter, 
Cruz et al. 2008) (Yaneva, Springer et al. 2009). In a molecular dynamics 
simulation of peptide-free MHC II (Painter, Cruz et al. 2008), we observed 
changes strikingly similar to those observed in the αF54C structure determined 
here, in particular, a change in pitch and partial unwinding of the 310 helix and 
concerted rotamer changes of αF51,αF45, αF48 and βF89 (Fig. 2.5, 3.17). The 
P1 pocket, a locus of conformational change in molecule 2 of the αF54C crystal 
structure, is known as a key determinant of MHC II-peptide interaction (Stern, 
Brown et al. 1994; Zarutskie, Sato et al. 1999; Tobita, Oda et al. 2003) and has 
long been proposed by numerous groups to be involved in DM catalyzed peptide 
exchange(Anders, Call et al. ; McFarland, Beeson et al. 1999; Chou and Sadegh-
Nasseri 2000; Stratikos, Mosyak et al. 2002; Pashine, Busch et al. 2003; 
Nicholson, Moradi et al. 2006; Narayan, Chou et al. 2007; Davies, Lamikanra et 
al. 2008) (Mosyak, Zaller et al. 1998). Finally, the α39-44 strand, which also 
rearranges in molecule 2 of the αF54C structure, carries two other residues in 
addition to αF51 implicated in DM-MHC II contact, αE39, which was identified in 
a random screen as a residue important in mediating DM’s functional effect 
(Doebele, Busch et al. 2000), and αW43, which was identified by mutagenesis as 
important in DM-DR binding (Anders, Call et al.).  Thus, the altered conformation 
observed in the crystal structure of molecule 2 of αF54C provides a structural 
explanation for the involvement of the regions previously implicated in DM-
mediated catalysis. 
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FIGURE 3.17 
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FIGURE 3.17. Model of peptide free WT molecular dynamics simulation 
shows similar motion in key residues involved with αF54C-CLIP 
conformational change. Top left shows N-terminal region of the simulation 
starting model with residues αF48, αF51 and β89 shown in sticks. Bottom left; 
90° rotation showing the orthogonal view of this region with the additional residue 
αL45. Right panels show the same view but after a 20ns molecular dynamics 
simulation. The dotted lines represent the trajectory of the 310 helical region 
before (left) and after (right ) the simulation 
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How does substitution of αF54 lead to changes in the 310 helix and 
flanking strands? The principal contact between the extended strand region α51-
54 and the remainder of MHC II is with the αF54 side chain, which lodges in a 
small hydrophobic cluster with αW43 and other aromatic side chains forming the 
side of P1 pocket. The side chain of residue αF54 appears to act as an anchor 
for the extended strand region. Except for main-chain hydrogen bonds formed 
with the peptide, the extended strand does not otherwise interact with the rest of 
MHC II, and so replacement of the phenylalanine side chain with alanine or 
cysteine would facilitate motion of that region. The nature of the structural 
changes in the entire α39-54 region, and the reduced B-factors for this region in 
the altered conformation, suggest that it represents a stable alternative 
conformation. In support of the hypothesis, MHC II proteins that contain glycines 
at the alpha 52 and 53 positions (G/G) can adopt stable alternate conformations 
in the 310 helix and adjacent strand region.  HLA-DQ alleles are the only such 
MHC II proteins to contain the G/G motif and therefore may represent a subset of 
MHC II proteins that have increased lability within the 310 helix and extended 
strand region. Interestingly, the HLA-DQ2 allele has a deletion at the Serine 53 
position is resistant to DM mediated peptide exchange, suggesting that 
alterations within the extended strand region can influence DM susceptibility 
(Fallang, Roh et al. 2008).  
Notably, the H/D exchange experiments show that several hydrogen 
bonds are weakened by the αF54C mutation, indicating a global destabilization 
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of peptide-MHC II interaction.  This result is consistent with the crystal structure, 
for which increased B-factors were observed all along the length of the peptide 
for molecule 2 of αF54C. Thus, the functional effect of the mutation extends 
beyond the region immediately adjacent to the αF54 mutation. Cooperative 
changes along the length of the peptide previously have been associated with 
DM function (Ferrante and Gorski). 
A model for how this conformation might function as an intermediate 
state in the DM-mediated peptide release pathway is shown in Figure 3.18. In 
this model, interaction of DM with the MHC II-peptide complex stabilizes a 
conformation with decreased MHC-peptide hydrogen bonding and 
rearrangements in the crucial P1 pocket (Fig. 3.18 red).  These structural 
alterations lead to reduced MHC II-peptide binding affinity and facilitated peptide 
release.  DM interaction with this intermediate form persists until binding by a 
peptide with sufficiently high affinity is able to shift the equilibrium back towards 
the original MHC II-peptide conformation with release of DM (Fig. 3.18 blue).  If 
an exchange peptide were not available, DM dissociation would lead to formation 
of the peptide-refractive empty conformation (Fig. 3.18 orange).  Thus the 
mechanism provides a potential role for a “push-off” peptide, recently suggested 
to be required for DM function (Ferrante, Anderson et al. 2008) Computational 
studies suggest that the conformation of the peptide-free protein has additional 
alterations at the N-terminal end of the binding site (Nojima, Takeda-Shitaka et 
al. 2003; Gupta, Hopner et al. 2008; Yaneva, Springer et al. 2009), with the  
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FIGURE 3.18. Model for the DM receptive conformation as an intermediate 
between the stable MHC II-peptide complex and the peptide-free MHC II 
protein.  Top view of the peptide binding groove, with helices shown as 
cylinders, and peptide main chain and αF51 and αF48 side chains shown in 
stick. Stable MHC II-peptide complex (blue), from crystal structures MHC II-
peptide complexes, with arrow denoting motion of the αF51 and 310 helical 
region. DM receptive conformation (red), from Mol2 of the αF54C structure. DM 
is shown as a cartoon surrounding the putative MHC II binding region at the N-
terminal side of the binding site. Peptide exchange is facilitated in this form.  
Peptide-free conformation, from molecular dynamics simulation model of the 
peptide-free MHC protein (Painter, Cruz et al. 2008). Arrow indicates movement 
of the entire αF51 to αG57 strand region postulated to be involved in the 
conversion to the peptide-refractive MHC II conformation (Painter, Cruz et al. 
2008). 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extended stand region occupying part of the canonical peptide binding site 
(Painter, Cruz et al. 2008), creating a peptide refractive state.  In the model 
shown in Figure 3.18, association with DM would reverse these interactions, 
providing a structural explanation for DM’s chaperone function (Kropshofer, Arndt 
et al. 1997; vogt, Moldenhauer et al. 1997) .  Whether or not peptide is released, 
partially bound, or fully bound in the DM-associated intermediate complex is not 
yet clear. Recently, a model has been put forward for the DM –mediated peptide 
release mechanism based on DM binding of HLA-DR2 variants, in which 
spontaneous release of peptide from the P1 pocket facilitates DM interaction 
(Anders, Call et al.).  In contrast, in the αF54C-CLIP complex reported here, the 
P1 pocket is fully occupied, and there are other structural changes including the 
310 helix and adjacent strand regions that appear to facilitate DM interaction. 
Numerous studies (Natarajan, Stern et al. 1999; Sato, Zarutskie et al. 2000; 
Tobita, Oda et al. 2003) suggest the P1 anchoring residue, for the alleles used 
therein, disproportionately stabilize the peptide within the groove. It is plausible 
that covalently bound MHC II-peptide complexes used within that study induced 
conformational changes within the MHC II that were not explored through the 
binding assays employed to develop the spontaneous release model 
Nonetheless, additional studies will be required to fully elucidate the peptide 
occupancy of the DM-MHC II complex. 
A detailed molecular understanding of the DM mediated peptide exchange 
mechanism has been elusive due to the lack of a structural model that 
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encompasses the dynamic interactions between DM and MHC II. The structures 
reported here describe the first characterization of conformational changes 
involved in peptide exchange by DM, and provides a structural model for the DM-
receptive conformation of MHC II intermediate between a stable MHC II-peptide 
complex and the peptide-free conformation. 
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METHODS 
Mutagenesis of plasmid DR1  
Point mutations were introduced into the alpha and beta chains of the MHC II 
allele, HLA-DR1 (DRA*0101, DRB1*0101) using the QuickChange site-directed 
mutagenesis system (Stratagene).  For each engineered mutation, a pML1 
plasmid vector (Frayser, Sato et al. 1999) containing either the alpha or beta 
chain of HLA-DR1, was used as a template, and primers designed to introduce 
the desired mutation were annealed and subsequently extended by temperature 
cycling using PfuUltra DNA polymerase. The parent DNA template was digested 
using Dpn1 endonuclease, and the engineered plasmids were then transformed 
into XL1-Blue competent cells.  The sequence of the entire mutant gene was 
confirmed before plasmids were transfected into E. coli BL21(DE3) pLysS cells 
for expression.  Primers were designed using the web based program PrimerX 
(www.bioinformatics.org/primerx/index.htm).  
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Protein production  
The extracellular domains of the recombinant HLA-DR1 alpha and beta chains 
were individually expressed in Escherichia coli inclusion bodies, isolated by 
denaturing ion exchange chromatography, and refolded in vitro as previously 
described (Frayser, Sato et al. 1999).  Refolded HLA-DR1 was purified by 
immunoaffinity chromatography using protein-A coupled conformation-specific 
anti-HLA-DR1 antibody LB3.1. Eluted protein was further purified by gel filtration 
(Superdex 200). The protein concentration was measured by UV absorbance at 
280 nm using an extinction coefficient of 54,375 M−1 cm−1 for HLA-DR1.  
 
HLA-DM expression and purification  
The soluble DM molecules with FLAG tag (Busch, Pashine et al. 2002) were 
produced by and secreted from  stably transfected Drosophila S2 cells and 
isolated by immunoaffinity chromatography from conditioned medium. Eluted DM 
complexes were further purified by size exclusion chromatography (Superdex 
S200). 
 
Peptide labeling/purification  
N-terminally acetylated HA peptide (Ac-PKFVRQNTLRLAT-OH) and CLIP 
peptide (Ac-VSKMRMATPLLMQ-OH) (21st century Biochemicals) were labeled 
with Alexa-488 tetrafluorophenyl ester (Molecular Probes) through primary 
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amines at position K2 for HA and K3 for CLIP.  Labeled peptides were purified 
from unreacted reagents and side products by reverse phase chromatography 
(Vydak C18), and subjected to MALDI to confirm the correct molecular weight. 
 
Polarization assays 
Peptide complexes were prepared by incubation of WT or mutant MHC II (150 
nM) with 25 nM Alexa-488 labeled CLIP for 3 days at 37°C in aluminum covered 
96-well non-binding surface, black polystyrene assay plates (Corning) in 200 µl 
binding buffer (100 mM Na citrate, 50 mM NaCl, 0.1% octyl glucoside, 5 mM 
EDTA and 1 mM PMSF. Intrinsic dissociation reactions were initiated of bound 
peptide was monitored after addition of 100-fold excess unlabeled HA peptide in 
50 µl binding buffer and were followed using by fluorescence polarization at 488 
nm excitation and 520 nm emission, using a BMG Polarstar plate reader. DM-
mediated peptide release was monitored using the same conditions with the 
addition of a variable concentration of DM added to the incubation mixture. All 
experiments were run in triplicate. Free Alexa-peptide, and unlabelled competitor 
controls were included in each experiment; typical values were 30 mP and 300 
mP respectively. Dissociation rate constants were determined by fitting data to a 
single phase exponential decay model using Graphpad Prism. The rate 
enhancement for peptide dissociation by DM was calculated as the slope of the 
linear rate vs. DM concentration plot, and the DM-enhancement factor calculated 
as this slope divided by the intrinsic (i.e. no DM) rate constant (Weber, Evavold 
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et al. 1996). Intrinsic rates estimated as the y-intercept of the rate vs. DM 
concentration plot were similar to the no DM values. 
 
Surface plasmon resonance  
All SPR experiments were carried out on a Biacore 3000 instrument using CM5 
chips. Running buffer was 10mM sodium citrate pH 5.5, 150mM NaCl, 3mM 
EDTA and 0.05% (v/v) surfactant P20   Protein was immobilized by standard 
amine coupling using EDC and NHS to activate the carboxyl groups on the CM5 
surface. In the standard ligand coupling procedure, excess activated dextran 
carboxylate groups are capped with ethanolamine. For surfaces capped this way 
we observed significant non-specific binding of DM at pH 5.5, presumably 
because of interactions with non-ionized carboxylic acids from the 
carboxydextran matrix (pKa ~5).  Instead we capped with a different reagent, 2-
amino-ethyl-sulfate, which maintains a negative charge at low pH, and observed 
low non-specific binding at pH 5.5.   Binding experiments were carried out using 
2-fold dilutions of peptide-free WT or F54C flowed over immobilized HLA-DM at 
30 ul/min. We used a 3 minute binding phase with kinetic injection parameters 
and followed by dissociation of complex in running buffer for 10 minutes. 
Regeneration of the DM coupled surface was carried out by flowing 50 mM 
CAPS pH 11.5 for 30 s until a stable baseline was reached.  Binding interactions 
were fit to a heterologous binding model using BIAeval software. 
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Protein crystallography 
 Crystals of αF54C CLIP complexes were grown at 4°C by hanging drop vapor 
diffusion over 12% polyethylene glycol 4000, 100 mM sodium acetate (pH 5.6), 
100 mM  ethylene glycol, 5 mM DTT with drops containing 1 µl of well buffer with 
1 µl of 8.5 mg/ml protein. WT crystals were obtained under the same conditions 
by streak seeding crushed F54C CLIP crystals.  For x-ray diffraction 
experiments, we soaked crystal in a cryoprotectant  (well buffer with 25% 
ethylene glycol) for 30 seconds prior to flash freezing in liquid nitrogen. 
Diffraction data for both the WT-CLIP and the F54C-CLIP, collected under cryo 
conditions at the National Synchrotron Light Source (NSLS) on the x29 beamline 
(λ=1.1 Å) from single crystals (WT: 0.1 x 0.05 x 0.05, F54C : 0.6 x 0.07 x 
0.07mm) using a ADSC Q315 detector, were processed with HKL2000 (McCoy, 
Grosse-Kunstleve et al. 2007). Initial phasing was obtained by molecular 
replacement using Phaser (McCoy, Grosse-Kunstleve et al. 2007) with 
coordinates from another HLA-DR1 structure (PDB code: 1PWY) as a search 
model. Multiple rounds of refinement and building were carried out using Phenix 
(Adams, Afonine et al.) and COOT (Emsley and Cowtan 2004). 
 
 
Hydrogen /deuterium exchange  
WT and αF54C were pre-loaded with HA peptide, buffer-exchanged into PBS pH 
7.2 and concentrated to a final protein concentration of 55 µM.  The exchange 
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assays were performed by diluting the MHC II-peptide complexes, or HA peptide 
alone, 1:10 into PBS in D2O, followed by incubation at 25°C over the time course 
indicated in figure 6. At each time interval we quenched the reaction by diluting 
the exchange mixture 1:10 into 1M glycine pH 2.7 at 4°C.   These conditions 
minimize the exchange of amide H/D.  Samples were then flash frozen on dry ice 
and stored at -40° until we measured the deuterium incorporation of the peptide 
backbone amide nitrogens of the HA peptide by LCMS.  All components of the 
LCMS in contact with the sample were chilled to 4° prior to data collection.  
Samples were thawed on ice and 5 ul was added to 5 ul ice cold buffer A (0.1% 
TFA in 2% ACN) and immediately injected by syringe into the on-line 
chromatography system. Chromatography was carried out using 2 Acclaim 
PepMap µ-precolumns (Dionex) in series. The first was a 1X15mm, C4 
PepMap300 column connected in series to the second, a 1X15 mm C18 
PepMap100 column. Mobile phase A, 0.1% TFA in 2% ACN, was flowing at 50 
µl/min at the time of injection to capture the MHC-pep complex on the C4 
column. The MHC-pep complex quickly dissociates in this solution, and the 
released peptide remain bound to the C4 column. The peptide is then rapidly 
eluted from the C4 column and partially retained on the C18 column by switching 
the mobile phase to 25% ACN (50 µl/min). The peptide is then eluted into the 
LTQ mass spectrometer for analysis. The LTQ was tuned in the +ESI enhanced 
mode with resolution on the HA peptide +2 ion by teeing 2 ul/ml HA into the flow 
stream. We scanned from m/z 450-1600 using capillary temperature 275.00 C° 
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and source voltage 4.5 kV. Spectra were acquired from m/z 450 to 1600 with a 
cycle time of ~1 sec corresponding to 10 summed microscans with the maximum 
ion time set at 200 ms. At each time point an average m/z value was calculated 
by summing each peak in the isotope distribution weighted by its relative 
abundance.  Average mass values were converted to fractional HD exchange by 
reference to the average mass observed for unexchanged free peptide in the 
same experiment.  Fractional HD exchange versus time curves were fit to a two-
phase exponential rise equation using GraphPad Prism.  
The expected isotope distribution for HA peptide was calculated from the 
atomic formula (C69H119N18O19) using Protein Prospector 
(http://prospector.ucsf.edu/prospector/mshome.htm).  For calculation of the 
expected mass distribution under various conditions, the probability of H-D 
exchange at each of the 12 peptide main chain amide hydrogens was estimated 
using a binomial equation, which assumes equal probability of exchange at each 
position. 
  P(k)= n! / (k!*(n-k)!)  * pk * (1-p)(n-k) 
where P(k) is the overall probability of finding k events in a total of n tries when 
each individual event has a probability of p.  Here n=12 for the twelve amide 
positions, p=0.9 for exchange into 90% D2O, and k is number of hydrogens 
exchanged. 
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Electron-transfer induced dissociation mass spectrometry 
HA peptide from WT and F54C MHC II complexes, as well as free HA were 
subjected to hydrogen deuterium exchange and chromatography as outlined in 
the HDx methods section. For the ETD experiments, we chose 2, 218 and 512 
minute time points for deuterium incubation of complexed peptide. Peptide was 
eluted off the on-line chromatography system and injected into an amaZon 
quadroploe ion trap intstrument. The ion trap was set to operate in positive ion 
mode. ETD data analysis: ETD spectra were processed using Bruker Daltonics 
software. The average mass of each of the ions was determined by calculating 
the intensity weighted average of the isotope envelope corresponding to each 
calculated ion species for the c and z generated fragments (protein prospector). 
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Chapter IV 
Conclusions and future directions 
The studies in this thesis were designed to address outstanding questions 
in the field of MHC II peptide presentation.  Understanding the conformational 
variability inherent in MHC II proteins at various stages of the peptide loading 
process is critical to understanding the basic principles involved with peptide 
binding as well as for developing a model that can explain the catalytic action of 
HLA-DM. Utilizing computational, biochemical and structural studies, models of 
both the peptide free conformation of HLA-DR1 as well as a trapped intermediate 
in DM mediated peptide catalysis were generated. 
 
Model for the peptide free MHC II 
Chapter II of this thesis described a model for the peptide free 
conformation of the MHC II HLA-DR1. Using molecular dynamics simulation as 
well as experimental probes sensitive to the peptide occupancy of HLA-DR1, the 
peptide-free state of the molecule was investigated. The model developed from 
the simulation revealed novel conformational changes concentrated near the 
region surrounding the P1 pocket.  Strikingly, these alterations in structure 
maintained the general shape and electrostatic environment of the entire peptide 
binding groove, and in particular, the P1 pocket. This structural “maintenance” 
was due to an unraveling of the alpha 50-59 region and subsequent movement 
into the peptide binding groove with the alpha F54 engaging the P1 pocket in a 
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similar manner as the original valine side chain of the peptide bound structure. In 
addition, the canonical hydrogen bonding network was recapitulated between the 
conserved residues of the beta chain with the unfolded alpha 50-59 region of the 
alpha chain that moved into the binding groove. Support for this model was 
generated using monoclonal antibodies as well as other MHC II binding proteins 
with epitopes on HLA-DR1 that were predicted to have altered accessibility due 
to the conformational changes induced upon peptide removal. There was good 
agreement with the binding of these probes to regions of HLA-DR1 that were 
predicted to undergo no change, moderate, or large changes based on the 
simulation model.  
Previous work has shown that there is more then one conformation of 
peptide-free MHC II proteins. Kinetic studies have determined that there are 
peptide averse as well as peptide receptive conformations, with the peptide 
receptive form generated immediately upon peptide release slowly and reversibly 
converting to a peptide-averse state over a few minutes (Rabinowitz, Vrljic et al. 
1998). However, detailed structural models of these states have not been 
defined. The model put forth in chapter II of this thesis presents a peptide free 
conformation, however whether this conformation reflects a peptide binding 
averse or receptive conformation is unknown.  It is conceivable that this model 
represents an averse form and that the engagement of the P1 pocket by the 
αF54 as well as the “maintained” hydrogen bonded N-terminal peptide binding 
region occlude the groove from potential peptide binding events. It could also be 
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that this model represents the kinetically unstable peptide receptive conformation 
and that engagement of the hydrophic P1 pocket allows the structure to not 
collapse or be altered so that productive binding could occur in the presence of 
peptide.  
Future studies designed to address the conformational differences 
between the peptide averse and receptive states, and whether the model put 
forth from the molecular dynamics simulation of the empty MHC II represents 
either of these kinetically described species are needed.  One possibility would 
be to test the hypothesis that engagement of the alpha F54 into the P1 pocket 
blocks peptide binding, and therefore creates a peptide averse conformation.  
Mutation of the phenylalanine to an alanine would eliminate the anchor effect of 
the bulky hydrophobic side chain into the P1 pocket.  Previous studies have 
developed methods for the assaying the fraction of peptide receptive and averse 
(Rabinowitz, Vrljic et al. 1998; Grotenbreg, Nicholson et al. 2007). Using peptide 
binding assays, the rate of peptide association could be measured both for 
freshly generated peptide free MHC II protein as well as for peptide free MHC II 
that was in an equilibrium state between averse and receptive.  This would allow 
a comparison to be made between WT MHC II, theoretically able to form the F54 
engaged averse conformation with a F54A mutant, which would be unable to 
form the same “stable” averse conformation.  If the model represented a peptide 
averse conformation mediated by F54 engagement, we would expect to see a 
larger percent of the peptide receptive conformation in a F54A mutant. 
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In addition to addressing this hypothesis, further information regarding the 
nature of the conformational state of the peptide free MHC II could be 
ascertained by developing a panel of monoclonal antibodies directed against the 
alpha chain of HLA-DR1. In a similar manner to work that has been done on the 
beta chain, monoclonal antibodies raised against the denatured alpha subunit 
could be screened for differential reactivity for peptide loaded and peptide free 
HLA-DR1 (Carven, Chitta et al. 2004). One confounding issue with this method is 
that the alpha chains for MHC II HLA-DR alleles are very similar in humans and 
mice, therefore, development of hybridomas specific for human HLA-DR-alpha 
would need to be carried out in an MHC II knockout strain in order to maximize 
the amount of epitopes generated.  
 
MHC II conformation dictates HLA-DM susceptibility and peptide catalysis 
Chapter III of this thesis described a model for an MHC II conformational 
intermediate in the DM catalyzed peptide exchange reaction. Using a novel 
hydrogen deuterium exchange mass spectrometry approach to mapping MHC-
peptide interaction, the relative strengths of the individual hydrogen bonds along 
the backbone of the peptide were measured while the peptide was bound to 
MHC II. The hydrogen bonds flanking both sides of the P1 pocket were shown to 
be the strongest of those along the peptide backbone. A point mutant at the 
alpha 54 position of HLA-DR1 was generated and shown to have weakened 
hydrogen bonds flanking the P1 pocket relative to WT MHC II-peptide. This 
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mutation resulted in an MHC II with exquisite susceptibility to DM mediated 
peptide release as well as an increase in affinity for DM relative to wild type MHC 
II. Crystallization studies of the F54C and WT CLIP bound complexes revealed 
an intact hydrogen bond network, therefore the differences observed in the 
strengths of the hydrogen bonds between the F54C and WT peptide complexes 
must be due to a dynamic process.  
These structural studies revealed that the F54C complex showed a 
conformational change in one molecule of the asymmetric unit, which was 
induced by a crystal contact at the alpha F51, an important DM contact residue. 
The F54C and WT structures were nearly isomorphic with similar crystal 
contacts, however, no such change was induced in the WT structure.  
The alpha F54 lodges into a hydrophic cluster that anchors the P1 
proximal strand region to the rest of the MHC II. It was postulated that removal of 
the bulky hydrophobic phenylalanine side chain by the F54C mutation, resulted in 
an MHC II that could adopt alternate conformations.  The fact that the alpha F51, 
which is not directly adjacent to the mutated F54 residue, participated in a crystal 
contact resulting in the entire 310 helix and adjacent strand region adopting an 
altered conformation suggests that this region would undergo a concerted 
change if DM contacted the same residue.   
Interestingly, the model that was generated from the molecular dynamics 
simulation described in chapter II of this thesis, revealed a similar set of 
concerted changes involving the alpha 310 helix and adjacent strand region.  Due 
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to the striking similarities, it is reasonable to think that the model for the peptide 
free MHC II and the crystal structure of the contacted F54C converge on a 
conformation accessible to the WT MHC II. The conformational changes present 
in both models may represent a kinetically unstable form of the protein such as 
those that have been described for the peptide receptive and/or the DM 
susceptible conformation of MHC II.  
Because of the increased affinity of the F54C MHC II for DM, it may be 
possible to generate a co-crystal of the MHC II-DM complex. A possible reason 
for the lack of a complexed crystal structure thus far, may be a result of the weak 
affinity of the soluble ectodomains of WT MHC II and DM. In addition, 
crystallization attempts may be stymied because the interaction may only 
proceed through an unstable intermediate that would not be amenable to 
crystallization. The F54C mutant may overcome these barriers and allow for a 
stable MHC II-DM complex.  
There is considerable debate in the field regarding the conformation of 
MHC II that DM recognizes. A recent model suggests that DM only recognizes an 
MHC II that is partially empty with no occupancy of the P1 pocket (anders 2011). 
Other models however, suggest that DM recognizes alternate conformations of 
the MHC II itself, with a particular emphasis on the structure, rather then the 
occupancy, of the P1 pocket (Sadegh-Nasseri, Natarajan et al.). The data 
presented in Chapter III of this thesis would support the latter model suggesting 
that structural rearrangements of the N-terminal peptide binding domain 
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determine susceptibility to DM, regardless of peptide occupancy. A definitive 
crystal structure of the co-MHC II-DM and/or ternary MHC II-pep-DM complex 
could help resolve these outstanding questions regarding the mechanism of DM 
mediated peptide catalysis. However, direct structural analysis would still leave 
questions related to the dynamic nature of this interaction unanswered, therefore 
other biochemical approaches could be employed to help elucidate the nature of  
the peptide MHC II interaction and how DM functions to alter these interactions. 
One such approach that would be particularly useful for defining the role of the 
canonical hydrogen bond network in terms of peptide affinity for MHC II, would 
be to expand on the hydrogen deuterium exchange / electron transfer 
dissociation mass spectrometry (HDx/ETD) work presented in chapter III of this 
thesis. 
Using this approach, a number of different questions related to the peptide 
MHC II interaction could be addressed. First, what is the relationship between 
MHC II pocket engagement of the peptide side with the hydrogen bond network. 
Numerous studies have tried to address this issue by manipulating at least one 
component of the MHC II-peptide interaction, and or by comparing alleles and 
extrapolating information based on intrinsic differences between the various 
complexes (Ferrante and Gorski ; Weber, Evavold et al. 1996; Busch, 
Rinderknecht et al. 2005; Narayan, Chou et al. 2007; Zhou, Callaway et al. 2009) 
Applying  HDx/ETD systematically to different MHC II-peptide complexes may 
broaden our understanding of how the two types of interactions that bind peptide 
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within the MHC II binding groove are related. One could use a panel of peptides 
that engage the pockets of the MHC II differently, and directly measure the 
effects along the hydrogen bonding network. Applying this methodology to 
different MHC II proteins may uncover inherent differences between how the 
allotypes bind peptides.  
We have not applied the HDx/ETD method to determining the effect of DM 
on the MHC II-peptide complex, although this method could generate compelling 
information regarding the mechanism of DM induced peptide exchange. The rate 
of HDx is dependant on pH, and is quenched at pH 2.6. DM mediates peptide 
exchange in acidic compartments and has been shown to be inactive at neutral 
pH, therefore the ideal pH to perform the assay would need to be empirically 
determined. A balance would have to be found for a pH that was low enough to 
enabled DM to function, while at the same time, high enough such that the rate of 
hydrogen deuterium exchange was still on a useful time scale.  
Another approach that could be employed to get a greater understanding 
of the dynamic nature of the peptide-MHC II interaction would be to use NMR. If 
the individual chains of the 50kD complex could be labeled and their respective 
peaks could be assigned, then the dynamic nature of the H-bond network 
extending from the MHC II to the peptide could be studied. In addition, the 
stability of the MHC II protein could be measured as a function of peptide affinity, 
of P1 occupancy and of peptide sequence.  
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In appendix I of this thesis, structural alterations in HLA-DQ alleles were 
examined. This analysis revealed that HLA-DQ alleles which contained a G/G 
motif at the alpha 52 and 53 positions were able to adopt alternate conformations 
in the alpha 3-10 helix and extended strand region. These motions are similar to 
what we see in the F54C structure, which is exquisitely susceptible to DM. It 
seems plausible that there is a connection between the lability we observed in 
the F54C protein and the changes observed around the alpha strand G/G region 
of the DQ alleles. One hypothesis that can be derived from these similarities is 
that the G/G/ motif in the HLA-DQ alleles creates a more DM susceptible MHC II. 
This hypothesis could be directly addressed by many of the methods described 
in Chapter III of this thesis. In particular, peptide release assays with titrations of 
DM as well as SPR binding experiments would be particularly useful in 
determining whether these alleles were more susceptible then MHC II proteins 
without the alpha G/G motif to DM mediated peptide release.  
The work presented in this thesis addresses MHC II conformational 
variability. By developing models for both the peptide free form of HLA-DR1 as 
well as a DM susceptible form of HLA-DR1, this work has expanded our 
understanding of the conformational heterogeneity of MHC II at various stages of 
the peptide loading process. The future studies proposed within this chapter 
would be valuable in broadening our overall understanding of the dynamic nature 
of proteins involved in antigen presentation. 
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A.1. Structural alterations in the alpha 3-10 helix for HLA-DQA1*01 alleles. 
There are many outstanding questions regarding DM catalyzed peptide 
exchange. In particular, structural changes in both DM and MHC II have been 
recognized as playing a role in the interaction of these molecules, although 
details have not been well defined (Sadegh-Nasseri, Natarajan et al. ; Ullrich, 
Doring et al. 1997; Chou and Sadegh-Nasseri 2000; Zarutskie, Busch et al. 
2001; Rotzschke, Lau et al. 2002; Belmares, Busch et al. 2003; Narayan, Chou 
et al. 2007). Therefore we have analyzed existing MHC II structures in order to 
gain insight into regions of structural variability that have been identified as 
being important regions for the DM-MHC II interaction (Doebele, Busch et al. 
2000; Pashine, Busch et al. 2003). Work presented in this thesis has identified 
the alpha 310 helix and adjacent strand region proximal to the P1 pocket as 
regions that undergo conformational changes at various stages of the peptide 
loading process. In addition, the work presented here suggests that lability 
within the alpha strand region of HLA-DR1 is a key determinant in DM mediated 
peptide catalysis. 
 
Our mutagenesis work has shown that when HLA-DR1 alpha F54 is 
mutated to an alanine or cysteine, the protein becomes exquisitely susceptible 
to DM, has altered peptide binding dynamics, and an increased propensity to 
adopt an alternate conformation. Examination of the structures for all MHC II 
peptide complexes to date has revealed that, with the exception of the region 
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around the prominent kink in the beta subunit alpha helix encompassing 
residues 57-70, the architecture of the peptide binding domain is maintained, 
and that side chain polymorphisms give rise to alterations in pocket structure.  
However, the HLA-DQ alleles have structural variations in the alpha 310 helical 
region, which correspond to the same regions that show alterations in both our 
empty dynamics simulation as well as our F54C structure.  The HLA-DQ alleles 
have been associated with disease, yet surprisingly little has been done 
towards understanding the structural differences that are apparent for this 
subset of MHC II proteins. Upon alignment of different MHC II proteins, the 
HLA-DQ structures were clear outliers and showed deviations from the other 
MHC II structures in the same regions that we described in our empty 
simulation model and our αF54C structure (Fig 1.5, 1.7); the latter of which we 
believe to have important implications for the dynamic nature of DM catalyzed 
peptide exchange. 
Intriguingly, each of the HLA-DQ alleles aligned show alterations in 310 
helical and adjacent strand region (Fig. 1.5, 1.7). The HLA-DQ0602 structure 
(1UVQ; A1*0102/B1*0602) and the HLA-DQ1 (3PL6; A1*0102/B1*0502) have 
the same alpha chain, yet differ in the conformation of the alpha 310 helix. An 
LSQ alignment was performed in order to gauge the magnitude of the 
alterations between the two HLA-DQ alleles when compared to each other and 
to HLA-DR1 (Fig 1.7).  This analysis revealed that the alpha 1 domains for the 
DQ alleles differed in main chain RMSD by less then 0.7 angstrom along the 
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entire domain, except for the 310 region from alpha 43 to alpha 55, where the 
average RMSD between the DQ alleles when compared to each other as well 
as to HLA-DR1, was around 2.0 angstroms (Fig A.1). Because the 1UVQ and 
3PL6 structures have the same alpha chains, we sought to determine whether 
there were features inherent to the peptide or the beta chain that could cause 
these disparate conformations in the alpha chain. 
The concerted conformational changes in the alpha 310 helical region 
can be summarized as follows: In the 1UVQ HLA-DQ structure, the hypocretin 
peptide contains a proline at the P2 position. The crystal structure of the 
complex shows that the peptide maintains the canonical type II polyproline twist 
conformation up until the P2 proline, which is next to the beta His 81 of HLA-
DQ (Fig A.1.1). The P2 proline could prevent the beta His 81 from adopting its 
normal rotamer (as seen in all other MHC II structures that have a His at this 
position) due to steric hindrance. A theoretical alteration of the beta His 81, 
placing it in its canonical rotamer shows that this change would create a 0.45 
angstrom clash with the proline at the P2 position (using coot for the 
modification and assessing by molprobability in phenix). This could be why 
there is an alternate rotamer seen in the 1UVQ structure that prevents the beta 
His 81 from forming a hydrogen bond with the main chain of the peptide. In 
addition, the beta Asn 82 OD1 cannot form a hydrogen bond to the P2 proline 
(Fig. A.1.1). Both the beta His 81 and Asn 82 hydrogen bonds have been  
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FIGURE A.1.1 
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FIGURE A1.1 Proline at the P2 position in the HLA-DQ bound peptide 
breaks key N-terminal hydrogen bonds. (top) Broken hydrogen bonds due to a 
proline at the P2 position in 1UVQ . Cartoon diagram of N-terminal region of the 
peptide binding domain with the peptide backbone shown as lines, with the 
proline at the P2 position shown in stick. Beta ASN 82 and H81 are shown in 
yellow. Dashed line indicates the hydrogen bond between the ASN 82 and the 
carbonyl of the proline. (bottom) Intact N-terminal hydrogen bonds in the 3PL6 
structure. The main chain of the P2 histidine is shown in stick and dashed lines 
indicate hydrogen bonds between both functional groups of beta ASN 82.  The 
beta H81 adopts the canonical rotamer and forms a hydrogen bond with the 
backbone of the peptide 
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implicated as key energetic factors in the peptide-MCH II interaction, and when 
mutated, have been shown to cause nearly spontaneous release of peptide 
from HLA-DR alleles (Narayan, Chou et al. 2007; Bandyopadhyay, Arneson et 
al. 2008; Zhou, Callaway et al. 2009). Therefore, the HLA-DQ proteins may 
have different requirements for the energetic contributions of hydrogen bonds 
with the beta 81 and 82 residues. Yet another effect of the P2 proline in the 
1UVQ structure is that the psi angle of the proline causes the peptide to kink 
toward the DQ alpha chain (the delta psi between the 1UVQ and the 3PL6 
peptides show a 347 degree deviation at the i+1 position).  
The HLA-DQA1*01 alleles are unique in that there are glycines at the 
alpha 52 and 53 positions (G/G), different HLA-DQ alpha chains, and all other 
MHC II proteins do not contain this motif as assessed by sequence alignment in 
the IMGT/HLA database. For all MHC II structures to date, the alpha 53 
position is the only residue that forms hydrogen bonds with the peptide 
backbone. In the 1UVQ structure, these hydrogen bonds are maintained, likely 
because the G/G sequence allows some level of flexibility in this region and can 
therefore accommodate the kink in the peptide through an alteration in their phi 
psi angles. Fig A.1.2. shows delta phi psi plots comparing the 1UVQ with the 
3PL6 (which have the identical alpha chain, and therefore the same G/G motif) 
as well as with 1DLH (HLA-DR1), which has an Ala 52 and Ser 53 in place of 
the G/G. The phi for the alpha Gly 52 and the psi for the alpha Gly 53 show 
major deviations when the 1UVQ is compared to 3PL6 as well as the 1DLH,  
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FIGURE A.1.2 
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FIGURE A.1.2. The Gly/Gly motif in the extended strand region for some 
HLA-DQ alleles allows alternate conformations of the alpha 310 helix. Delta 
phi psi plots comparing the 1UVQ with the 3PL6 (top), 1UVQ vs 1DLH (HLA-
DR1) (middle) and 1DLH vs 3PL6 (bottom), phi values are represented in red 
and phi are in green. Residues are shown on the x-axis and delta phi/phi are 
shown on the y-axis 
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however, there is a relatively small difference for the alpha 52 and 53 positions 
when the 3PL6 and the 1DLH structures were compared. When phi psi angles 
for all of the residues that comprise the alpha 310 helix were compared, the only 
major deviation was at the G/G region, implicating these residues as 
contributing to the conformational change that propagated along the entire 
alpha 310 helical region (Fig. 1.7). These analyses suggest that the G/G motif is 
able to accommodate both canonical and altered conformations.  
It is reasonable to think from this analysis that the structure of the 
peptide is influencing the conformation of the alpha 310 helical region and that a 
proline in the P2 position is the key structural factor promoting a distortion of 
the G/G motif in the 1UVQ alpha chain which then propagates to the alpha 
W43.  Interestingly, the W43 in the 1UVQ structure is in a pointed away from 
the base of the peptide binding groove (Fig. A.1.3). The 1UVQ structure is 
unique in that this is the only solved MHC II peptide structure to show the alpha 
W43 in this rotamer. The conformational change in the 310 alpha helix positions 
the carbonyl from the Gly 52 such that it would clash with the W43 if the W43 
maintained it’s canonical rotamer, which is normally tucked into a hydrophobic 
cluster that forms a side of the P1 pocket.  Interestingly, the alpha W43 has 
been implicated in the DM-DR interaction, when mutated, the interaction is 
abrogated (Anders, Call et al.). 
Another HLA-DQ allele, (HLA-DQA1*0501/B1*0201; IS9V) also has 
structural changes in the regions described above. Interestingly, there is a  
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FIGURE A.1.3
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FIGURE A.1.3. Alpha W143 can adopt different rotamers in HLA-DQ alleles 
that contain the alpha strand Gly/Gly motif. (top) The alpha W143 is pointed 
away from the peptide binding groove. (bottom) The 3PL6 structure showing the 
W143 in the canonical rotamer. The alpha Gly 52 is indicated for both structures, 
note the position of the carbonyl from the Gly 52 would create a steric hindrance 
on the W43 if the W43 were in it’s canonical rotamer (as seen in the bottom 
panel). 
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deletion of the alpha Ala 52, which causes the alpha Phe 51 to be tucked into 
the N-terminal side of the peptide binding groove, which theoretically could 
inhibit the interaction with DM, since this has been shown to be a critical DM 
interaction residue (Doebele, Busch et al. 2000).  Indeed, this particular HLA-
DQ allele has been shown to be resistant to the effects of DM catalyzed peptide 
exchange(Fallang, Roh et al. 2008).  However, based on the analysis for the 
HLA-DQ alleles that contain the G/G, it can not be ruled out that the Ala 52 
deletion influences the lability within the stand region proximal to the P1 pocket 
and in that way creates a DM resistant phenotype. 
 
Using the SYFPEITHI database, we performed a search for peptides 
associated with MHC II alleles and found that proline is predicted in the i+1 for 
peptides known to bind HLA-DQA1*01 alleles, but not for the majority of MHC II 
alleles (data not shown). A thorough structural analysis of different MHC II alleles 
complexed with peptides that have a proline at the P2 position may help identify 
whether the peptide itself can contribute to alterations in the N-terminal peptide 
binding region. In addition, studies of DM susceptibility for MHC II peptide 
complexes that have the Gly52 Gly53 motif may also indicate whether flexibility 
in this region is important for the mechanism of DM mediated peptide release.  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A.2 Expression of HLA-DR1 in E. Coli (Fermentation) 
Protocol from Mia Rushe 
 
Procedure: 
 
Day 1: 
1. Streak an LB-amp (or kan if kanamycin resistant strain, chlor also if cells 
are pLyss) plate in the evening with BL21 cells of interest from frozen 
stocks.  Incubate at 37˚C overnight. 
Day 2: 
1. Put streaked plate at 4˚C in morning, sealed with parafilm. 
2. Autoclave assembled fermentor filled with 10 L of 1 x LB broth, 1 L of 
distilled H2O, 1 L of 1 x LB broth, at least 150 mL 20 % glucose, and 3-
125 mL Erlenmeyer flasks. 
3. In the early evening, add 83 mL sterilized LB broth to one of the sterile 
flasks. Add 83 mL Ampicillin (50 mg/mL) and 1.2 mL 20 % glucose.  **IF 
the cells are kanamycin resistant, substitute 83 mL of a 50 mg/mL stock 
of kanamycin sulfate for ampicillin. If cells are pLyss, add 83 mL 
chloramphenicol (35 mg/mL).**  
4. Mix well and take a 1 mL blank sample for OD600 measurements.  You 
may want to add 1 mL 20 % NaN3 to prevent growth in the blank sample.  
Keep this blank in a plastic cuvette. 
5. The remaining LB solution will be split into different containers.  Pipet 2 
mL into a sterile 15 mL conical tube, 20 mL into a 50 mL conical tube, and 
20 mL into each of the remaining sterile Erlenmeyer flasks.  Label the 
flasks 1, 2 and 3. 
6. Pick one colony from your plate.  Add it to your 15 mL tube and vortex 
vigorously.  Take 200 mL of that tube and add it to the 50 mL conical tube 
and vortex vigorously.  Take 200 mL of that tube and add it to Erlenmeyer 
flask #1 and swirl a lot.  Take 200 mL from that flask and add it to 
Erlenmeyer flask #2 and swirl a lot.  Take 200 mL of that flask and add it 
to Erlenmeyer flask #3. 
7. Grow the 3 Erlenmeyer flasks on a shaker table at 37˚C overnight. 
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GROWING BL21 IN A 10 L FERMENTOR, Page 2 
Protocol from Mia Rushe 
 
Day 3: 
1. Measure the absorbance at 600nm of each flask compared to the blank you 
saved.  Pick the one that is less than 1.0 OD600, but still has measurable 
growth in it. (0.7 is about ideal.) 
2. Set up the fermentor:  Add 10 mL of Ampicillin, 50 mg/mL, 100 mL 20 % 
glucose (sterile), and 200 mL antifoam A.  **IF the cells are kanamycin 
resistant, substitute 10 mL of a 50 mg/mL stock of kanamycin sulfate for 
ampicillin.  If  the cells are pLyss, also add 10 mL 35 mg/mL 
chloramphenicol.**  Mix well.  Remove 1 mL as a blank and store in a 
plastic cuvette, possibly with 1 mL 20 % NaN3. 
3. Run the mixer on the fermentor at ~700 rpm, and run the air at 15 psi and 5 
LPM.  Watch for excessive foaming and add antifoam if it is necessary.  **If 
you have never set the fermentor up before, ask for help!! 
4. Seed the fermentor with 10 mL of the overnight flask you selected. 
5. Take samples and check the OD600 every hour until you get close to 1.0, 
and then check more frequently.  Do not overgrow! 
6. When the OD600 reaches 1.0, take a 1 mL sample “not induced.”  Spin 
down and re-suspend in 1x urea-SDS loading buffer. Freeze at –20˚C. 
7. Add IPTG to 0.75 mM final concentration.  I use 10 mL of 0.75M IPTG 
stock (1000 x).  Allow to grow for 2-5 hours with IPTG. (Longer for class I 
MHC subunits) 
8. Take a 1 mL sample “induced.”  Spin down and re-suspend in 1x urea-SDS 
loading buffer.  Freeze at –20 ˚C until you are ready to check the “not 
induced” and “induced” samples on a gel by SDS-PAGE. 
9. Spin down all the cells at 8000 x g and discard the supernatant.  For 
inclusion bodies, you may freeze the pellet at –20˚C, or proceed with the 
inclusion body prep through the DNAse step and freeze at –20˚C. 
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BL21 MEDIA RECIPES 
Protocol from Lauren Angelo 
 
  Modified LB      2x YT + Salts     Terrific 
Broth 
10 g/L tryptone   16 g/L tryptone   12 g/L 
tryptone 
5 g/L yeast extract   10 g/L yeast extract   25 g/L yeast 
extract 
0.4-1% glucose   0.4-1% glucose   0.4-1% 
glucose 
5 g/L NaCl    100 mL/L 10x Salts*  100 mL/L 
10x Salts* 
5 g/L K2HPO4 
10 mM MgSO4 
1 mL/L Trace Elements 
 
 
  *10x Salts 
23.1 g/L KH2PO4 
125.4 g/L K2HPO4 
**filter-sterilize—do 
not autoclave. Add 
to media after other 
ingredients have been 
autoclaved** 
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A.3 Inclusion body prep for HLA-DR1 subunits 
Protocol from Mia Rushe 
 
Procedure (for pellet from 10 L culture): 
 
1. Spin down cells at 5000 x g—collect supernatant into a container, sterilize 
with 1% Wescodyne for 10-20 minutes, and then dump down the sink. 
2. With a rubber spatula, re-suspend fresh bacteria into a single plastic 
container with ~200 mL Sucrose Solution. 
3. Chop the solution briefly in a homogenizer or polytron. **Do not sonicate! 
4. If cells are not pLyss, add 1 mg dry lysozyme per mL suspension (0.2 g) 
and stir for 10 minutes.  If cells are pLyss, just stir for 10 minutes. 
5. While stirring, add 500 mL Deoxycholate-Triton Solution.  Solution will 
become very viscous due to cell lysis and DNA release. 
6. Add 1 mL of 4 M MgCl2 Solution to make 5 mM final concentration. 
7. Add 2 mL DNAse Solution.  Stir until the solution is the viscosity of water. 
8. Freeze overnight at –20˚C, or until ready to complete the prep. 
9. Thaw solution in warm water bath. 
10. Stir an additional 10 minutes after thawing to allow the DNAse to work 
again. 
11. Spin down in 2 centrifuge bottles at 8000 x g for 20 minutes. Discard 
supernatant. 
12. Re-suspend pellets in 300 mL or more each Triton Solution.  Chop briefly, 
keeping the pellets on ice as much as possible.  Spin down at 8000 x g for 
20 minutes and discard supernatant. 
13. Repeat step 12 three or more times. 
14. Re-suspend pellets into 300 mL or more each Tris Solution.  Chop briefly, 
keeping the pellets on ice as much as possible. Spin down at 8000 x g for 
20 minutes and discard supernatant. 
15. Repeat step 14 two or more times. 
16. Re-suspend/dissolve the pellets and chop in ~ 200 mL Urea Solution. 
17. Spin down at 20˚C, 15,000 x g for 30 minutes.  Filter through a 0.2 mm 
filter. 
18. Freeze at –70˚C until ready to purify by Urea HQ. 
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INCLUSION BODY PREPARATION FOR HLA-DR1 SUBUNITS                                                    
Protocol from Mia Rushe 
 
Solutions (**Note: Do not add DTT until just before use!): 
 
        
Sucrose Solution 
   50 mM Tris, pH 8.0       
   25 % sucrose       
   1 mM EDTA      
   0.1 % NaN3       
   10 mM DTT      
Deoxycholate-Triton Solution 
   1 % Deoxycholic Acid      
   1 % Triton X-100         
   20 mM Tris, pH 7.5       
   100 mM NaCl         
   0.1 % NaN3           
   10 mM DTT        
Triton Solution 
   0.5 % Triton X-100    
   50 mM Tris, pH 8.0       
   100 mM NaCl    
   1 mM EDTA       
   0.1% NaN3    
   1 mM DTT     
Tris Solution 
   50 mM Tris, pH 8.0    
   1 mM EDTA    
   0.1% NaN3    
   1 mM DTT     
Urea Solution 
   8 M Urea     
   20 mM Tris, pH 8.0    
   0.5 mM EDTA    
   10 mM DTT     
DNAse Solution (**make 50 mL total, not 1L**) 
   75 mM NaCl    
   50 % glycerol      
   2 mg/mL DNAse    
  (Sigma D-5025 or DN25) 
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A.4 Making Urea Solutions 
Protocol from Mia Rushe 
 
Procedure: 
 
1. Add concentrated buffer stock solution, any additives (such as EDTA or 
NaCl), and dry urea (FW = 60.06).  Add ddH2O to an appropriate volume 
to make 8 M Urea. 
2. Stir slowly—you can warm in a bucket of water, but do not warm too 
quickly or too much. 
3. After urea is dissolved, add Sigma mixed bed resin TMD-8, ½ teaspoon at 
a time until the beads stop turning yellow in the solution (i.e. there are a lot 
of blue beads). 
4. Stir slowly another 10 minutes, and then let the beads settle. 
5. Filter using a 0.2 mm membrane. 
6. Store at –20˚C if you are not going to use immediately. 
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A.5 Urea HQ Inclusion body Purification for HLA-DR1  
Protocol from Mia Rushe 
 
Column: HiTrap Q XL column, GE Healthcare 
 
Buffers: Solution A: 8 M urea, 20 mM tris, 1 mM DTT added just before use 
   Solution B: 8 M urea, 20 mM tris, 1 M NaCl, 1 mM DTT added just 
before use 
  For purifying A1S, both solutions should be pH 8.0 
  For purifying B1S, both solutions should be pH 9.0 
 
Procedure: 
1. Make approximately 3 L solution A and 1 L solution B, using the 
protocol for Making Urea Solutions.  Use the appropriate pH for the 
inclusion body you will be purifying.  If not using immediately, store at -
20°C.  Do not add the DTT until just before use. 
2. Thaw urea-solubilized inclusion bodies.  For B1S, adjust the pH to 9.0 
using NaOH. (pH should be 8.0 in frozen inclusion bodies) 
3. Equilibrate the HQ column in 1-5 column volumes solution A. 
4. Flow the inclusion body solution over the column.  If it is very 
concentrated, it may bind better if it is diluted 1:2 in solution A.  **NOTE: 
Save flow-through of the column, as the protein is very concentrated and 
may saturate the column.** 
5. Run a gradient of 0-30% solution B (1-300 mM NaCl) over 6 column 
volumes.  Collect fractions. 
6. Analyze fractions from all major peaks by SDS-PAGE.  **NOTE: If the 
protein peak of interest looks different when run on reducing vs. non-
reducing SDS-PAGE, add more DTT to the final inclusion body pool to 
completely reduce the protein.** 
7. Pool peak fractions and measure the concentration of protein using 
absorbance at 280 nm against a blank of solution A.  **NOTE:   For A1S: 
1.3 OD280 = 1 mg/mL.    For B1S: 1.7 OD280 = 1 mg/mL. 
8. For B1S, adjust the pH back to 8.0.  Add EDTA to a final concentration of 
5 mM (10 µL 0.5M EDTA stock / mL inclusion body solution). 
9. Store in convenient aliquots at -80°C. 
 
**NOTES: A new HQ column has a protein binding capacity of about 5-10 
mg / mL resin.  The capcity becomes significantly lower over time with this 
procedure, possibly in part due to EDTA.  Regeneration does not seem to 
be particularly helpful.  Thus, when loading protein, do it slowly and 
monitor the absorbance of the flow-through to determine when the protein 
is no longer binding to the resin.  The chromatograms will be very messy 
and inconsistent, but the refolding yield for inclusion bodies purified in this 
manner is much better.** 
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A.6 Refolding HLA-DR1 
Protocol from Mia Rushe 
 
Procedure: 
 
7. Chill Refolding Mix without glutathione to 4˚C.  Refolding should be done 
in a container close to the size of the volume of liquid to reduce exposure 
to air.  De-gas solution by sparging with argon for about 20 minutes. 
8. Add glutathione (oxidized and reduced) and stir until just dissolved. 
9. Stir as rapidly as possible 
10. Add peptide—about 5-fold molar excess in a 1x refolding is good, so you 
should end up with a final peptide concentration of 0.4 mM.  You can use 
the same concentration peptide for a 2x re-folding.  **Note: If you want to 
re-fold empty DR1, simply omit the peptide. 
11. Slowly (dropwise) add HQ-purified inclusion bodies in urea. Add 2 (1 x) or 
4 (2x) mg of each inclusion body (alpha and beta) per liter of Refolding 
Mix. 
12. After everything is well mixed, cover tightly and store at 4˚C for at least 36 
hours. 
 
 
Refolding Mix: 
   20 mM Tris, pH 8.5 
   0.5 mM EDTA 
   25 % glycerol 
   2 mM glutathione, reduced  ** Add just before use! 
   0.2 mM glutathione, oxidized ** Add just before use! 
 
Example 2 x re-folding, 4 L total volume: 
   80      mL of 1 M Tris, pH 8.5 
4        mL of 0.5 M EDTA 
1000  g glycerol 
2.45  g glutathione, reduced 
0.488 g glutathione, oxidized 
16 mg DRA1S inclusion bodies (8 mL of 2 mg/mL stock, Urea HQ pure) 
16     mg DRB1S inclusion bodies (16 mL of 1 mg/mL stock, Urea HQ pure) 
1.6     mmoles Ha peptide (800 mL of 2 mM Ha peptide stock) 
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A.7 Folded HLA-DR1 ELISA  Protocol from Mia Rushe  
Procedure:   1. Coat Immulon IV plate (from Dynex) with 100 µL per well α‐DR monoclonal antibody LB3.1 or L243, diluted 1:1000 in plain PBS.  Stock is 1.8 mg/mL in PBS, 0.02% NaN3.  Incubate plate on nutator for 2 hours at 37˚C or overnight at 4˚C. 2. Wash each well 3 times with PBST Solution. 3. Block the plate by filling each well to the top with Block Solution. Incubate at least one hour on nutator at 37˚C.  The plate can be stored at this point if the Block Solution is replaced by Dilution Solution.  Store plates at 4˚C, covered in packing tape and surrounded by plastic wrap. 4. Remove Block Solution or Dilution Solution in stored plates.  Add 50 µL fresh Dilution Solution to each well. 5. Make up standards of folded DR1 in dilution solution.  Make high concentration of 2 ng/µL as the high concentration, and dilute 1:2 down to 0.002 ng/µL.  Add 50 µL of standard per well, giving 100‐0.1 ng/well—make sure to do duplicate measurements of the standards.  Also, include a blank measurement. 6. Add samples and diluted samples into wells.  A good way to test most refolding mixes is to add 50 µL, 5 µL, and 2.5 µL of sample to give the dilutions, making up the difference to 50 µL with dilution solution (0 µL, 45 
µL, and 47.5 µL). 7. Incubate plate on nutator for 1 hour at 37˚C, 2 hours at room temperature, or overnight at 4˚C. 8. Carefully wash each plate 3 times with PBST, avoiding spillover from neighboring wells. 9. Add 100 µL/well of rabbit CHAMP polyclonal α‐DR1 antibody diluted 1:25,000 (or 1:500 of a 1:50 stock solution) in Dilution Solution.  Incubate plate on nutator for 1 hour at 37˚C, 2 hours at room temperature, or overnight at 4˚C. 10. Wash wells 3 times with PBST.  ** Follow Alternate Procedure after this point for Europium Staining (following page) 11. Add 100 µL goat α‐rabbit IgG peroxidase (HRP) conjugate (from Roche) diluted 1:4000 in dilution solution.  No azide should be present at this step, as it inhibits the enzyme.  Incubate on nutator 0.5‐2 hours at room temperature or 37˚C.  **Background increases if this step is allowed to sit overnight at 4˚C. 12. Wash wells 3 times with PBST. 13. Add 200 µL ABTS Solution to each well. 14. Read absorbance in ELISA plate reader at 405 nm. 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15. To stop plate from developing, add 50 µL Stopping Solution to each well. 16. Try several absorbance readings to catch the solutions at the most informative stage of developing—before saturation. 17. Use a 4‐parameter curve fit to the standards to determine the MHC class II concentration of the samples. 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A.8 Preparation of Antibody Protein A Immunoaffinity Column 
Developed by Mia Rishe 
 
Materials: 
200 mM Borate: 1.24g /100 mL, titrate to pH 9.0 with NaOH 
200 mM Ethanolamine: 1.2mL/100 mL, titrate to pH 8.0 
Antibody solution, enough to have 10 mg/5mL matrix 
Protein A-coupled matrix; I prefer IPA-400 Fast-Flow. 
PBS + 0.02% NaN3 
Dimethylpimelimidate (20 mM final, (MW=259), 5.18 mg/mL)   
Advice: Use a fresh bottle (e.g. unopened) every time 
 
Procedure: 
 
1) Mix Antibody and ProteinA matrix in PBS, preferably with as small a volume 
as possible (ideally ~15 mL if using 5 mL matrix; can be scaled up 
accordingly).  This can be done in a polypropylene centrifuge tube, or directly 
in the gravity column body (just make sure the ends are sealed)  Rotate at 
room temperature 1 hour or longer.  Remove 15 mL of suspension into tube 
labeled “TOTAL”.  
 
2) Spin 2000 rpm 5 min, remove and save supernatant and pellet.  Or, if using 
the column, let the solution drain out.  Remove 15 mL of supe into tube 
labeled “NON-BOUND”.  
 
3) Resuspend pellet in 50 mL borate solution, spin/drain, remove supernatant. 
 
4) Resuspend pellet in 15 mL fresh borate solution.  Remove 10 mL into tube 
labeled “BOUND”.  Add 20 mM final dimethylpimelimidate as solid (77.7 mg 
for 15 mL) and dissolve.  Rotate 30 minutes at room temperature (going 
longer will over-couple the matrix) 
 
5) Spin/drain to remove supe and check that the pH of the supe is > 8.0. 
 
6) Resuspend pellet in 50 mL ethanolamine, rotate 30 minutes room 
temperature or longer, spin/drain off supe. 
 
7) Wash pellet with 50 mL ethanolamine, then 50 mL borate, then 50 mL PBS 
 
8) Resuspend pellet in 15 mL PBS.  Remove 15 mL of suspension into tube 
labeled “NON-COUPLED”.  Store matrix at 4°C in PBS + NaN3. 
 
Analysis: 
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Add 10 mL 2x Laemlli buffer to each fraction, boil, and spin in microfuge. 
Run 10% SDS-PAGE of MW markers, 1 mg mouse IgG, and 10 mL of each 
fraction taken.  Gel should show heavy and light chains in TOTAL and BOUND, 
and nothing in NON-BOUND and NON-COUPLED.  If there is more protein in 
NON-BOUND than BOUND, try a different binding buffer (PBS works fine for 
LB3.1/L243).  If there is any protein in NON-COUPLED, cycle the matrix through 
all binding and elution conditions that will be used in the affinity purification 
procedure, and next time use fresh pimelimidate! 
 
 
 
Sample of analysis gel: 
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A.9 Immunoaffinity purification of HLA-DR1 
Protocol from Mia Rushe  
 
1. Concentrate folding mix and switch buffers into 1x PBS, pH ~7.  Make 
sure there is no glutathione, as that will ruin the antibody column! If the 
DR1 is from an insect cell prep instead of an E.coli refolding, make sure 
the supernatant has been filtered through a 0.2 mM filter. 
2. Flow the protein solution over a Protein A sepharose pre-column and then 
the LB3.1 or L243 column by gravity. Be sure to use a safety loop so that 
the columns don’t dry out. Save the flow-through to check on a gel. 
3. Wash with at least 10 column volumes of cold PBS 
4. Elute using high pH for DR1.  Use ~5 column volumes of 50 mM CAPS, 
pH 11.5 and collect 1 mL fractions into tubes with 300 mL of 300 mM 
NaPi, pH 6.0 to neutralize them.  Make a blank fraction for zeroing the UV-
VIS. (**Note: low pH may be used to elute, using 5 column volumes 50 
mM glycine, pH 2.6, and collecting 1 mL fractions into tubes containing 
300 mL of 300 mM Tris, pH 8.0 in them. This will give a lower yield for 
DR1, but may be better for other alleles.) 
5. Clean the column with pH swings: 
a. 3 column volumes 50 mM glycine, pH 2.6 
b. 3 column volumes 50 mM CAPS, pH 11.5 
c. 3 column volumes 50 mM glycine, pH 2.6 
6. Wash the column with at least 10 column volumes of PBSZ—until the pH 
is neutral. 
7. Check the Abs280 of the fractions and pool the protein-containing fractions. 
You may add azide to 0.02%, add peptide if the complex is empty and you 
wish to load a particular peptide, or dialyze/concentrate into 20 mM tris, 
pH 8.0 if you wish to further purify by ion exchange. 
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A.10 Loading HLA-DR1 with peptide 
Protocol from Zarixia Zavala-Ruiz 
 
Procedure: 
 
1. Obtain the empty MHC at a concentration of ~ 1 mg/mL, about 20 mM, in 
a suitable buffer such as PBS pH 7.0 with 0.02% sodium azide and 5 mM 
EDTA as protease inhibition. 
2. Add the peptide of choice to a final concentration of at least 100 mM, or 5-
fold molar excess. 
3. Incubate the mixture at 37°C for 3 days.   
4. Purify the peptide-loaded complex by gel filtration. **Make sure to save a 
sample of the unloaded complex to test by SDS-PAGE and analytical gel 
filtration.  Peptide loading will shift the MHC complex to a later time on a 
gel filtration column, and it will often cause SDS stability in a gel, as 
opposed to the empty MHC, which will break down into subunits. 
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A.11 LCMS/HDx for MHC II bound or free peptide 
Preparation of sample for LCMS/HDx 
1. Dry 1 ml of PBS and reconstitute with 1ml of D2O-H20) 
2. Add 10 µl of 1 M Gly-HCl (pH 2.7) to 0.6 ml tubes and put on ice 
Samples (start timing when mixed w D2O, incubate at room temp): 
1. 2.6 µl DR1-HA (from Corrie) + 23.4 µl D2O-PBS 
2. 5 µl HA (from Corrie) + 45 µl D2O-PBS 
3. 12 µl F54C-HA + 108 µl D2O-PBS 
Take 1, 5 and 5 µl aliquots of samples 1 – 3 respectively at specified time points, 
mix with 10 µl of 1 M Gly-HCl (pH 2.7) in normal water at 0o and immediately 
freeze at -80o.  
Take 1, 5 and 5 µl aliquots of samples 1 – 3 respectively at specified time points, 
mix with 10 µl of 1 M Gly-HCl (pH 2.7) in normal water at 0o and immediately 
freeze at -80o.  
LCMS: 
Columns: 1X15 mm C4 (300A) connected to a 1X15 mm C18 (Pepmap). 
Both columns and injector kept in ice bath. 
Mobile phases: A=0.1% TFA in 2% ACN. B=0.1% ACN in 25% ACN. Flow 
50 µl/min. Adjust %B to give ~5 min HA retention time (~18%). 
LCQ: Tune +ESI enhanced resolution on HA +2 ion by teeing 2 µl/min 1 
mg/ml HA into flow stream. Scan from m/z 450 – 1600 using the following 
values. 
Capillary Temp (C): 275.00 
Sheath Gas Flow (): 15.00 
Aux Gas Flow ():  20.00 
Sweep Gas Flow (): 2.00 
Source Voltage (kV): 4.50 
Full Micro Scans: 10 
Full Max Ion Time (ms): 200.00 
 
 
 
Sample handling: 
Remove one time point from -80o, quickly thaw in hand, draw 5 µl into cooled 10 
µl syringe and inject ASAP. After peaks have eluted, inject next time point by 
same procedure 
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A.12 Peptide Sequences 
 
HA: 
Ac-PKFVRQNTLRLAT-OH 
 
Clip: 
Ac-VSKMRMATPLLMQ-OH 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A.13 HLA-DR1 Protein Construct 
 
Chain A: 
IKEEHVIIQAEFYLNPDQSGEFMFDFDGDEIFHVDMAKKETVWRLEEFGRFAS 
FEAQGALANIAVDKANLEIMTKRSNYTPITNVPPEVTVLTNSPVELREPNVLICFI
DKFTPPVVNVTWLRNGKPVTTGVSETVFLPREDHLFRKFHYLPFLPSTEDVYD
CRVEHWGLDE  
PLLKHWEFDA 
 
Chain B: 
GDTRPRFLWQLKFECHFFNGTERVRLLERCIYNQEESVRFDSDVGEYRAVTEL
GRPDAEYWNSQKDLLEQRRAAVDTYCRHNYGVGESFTVQRRVEPKVTVYPSK
TQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVSTGLIQNGDWTFQTL
VMLETVPRSGEVYTCQVEHPSVTS  
PLTVEWRA 
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A.14 HLA-DR1 alpha gene sequence  
Gene 
Construct 
HLA-DR1 AS (α chain, short) and AL (α chain, long) 
Plasmid Full length in pHN1 (T7 promoter) called pDRA10 
Short version in pLM1 (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Mia Rushe in Larry Stern’s lab 
Sites used 
for cloning 
EcoRI and HindIII 
Insert size ~580bp AS, ~600bp AL 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
gaattcaggaggaatttaaaatgATCAAAGAAGAACATGTGATCATCCAGGCCGAGTT
CTATCTGAATCCTGACCAATCAGGCGAGTTTATGTTTGACTTTGATGGTGAT
GAGATTTTCCATGTGGATATGGCAAAGAAGGAGACGGTCTGGCGGCTTGAA
GAATTTGGACGATTTGCCAGCTTTGAGGCTCAAGGTGCATTGGCCAACATA
GCTGTGGACAAAGCCAACTTGGAAATCATGACAAAGCGCTCCAACTATACT
CCGATCACCAATGTACCTCCAGAGGTAACTGTGCTCACGAACAGCCCTGTG
GAACTGAGAGAGCCCAACGTCCTCATCTGTTTCATCGACAAGTTCACCCCA
CCAGTGGTCAATGTCACGTGGCTTCGAAATGGAAAACCTGTCACCACAGGA
GTGTCAGAGACAGTCTTCCTGCCCAGGGAAGACCACCTTTTCCGCAAGTTC
CACTATCTCCCCTTCCTGCCCTCAACTGAGGACGTTTACGACTGCAGGGTG
GAGCACTGGGGCTTGGATGAG 
short: 
CCTCTTCTCAAGCACTGGGAGTTTGATGCTtaaaagctt 
long: 
CCTCTTCTCAAGCACTGGGAGTTTGATGCTCCAAGCCCTCTCCCAGAGACT
ACAGAGAAC taaaagctt 
Protein 
Sequence 
iqeefkMIKEEHVIIQAEFYLNPDQSGEFMFDFDGDEIFHVDMAKKETVWRLEEFG
RFAS 
FEAQGALANIAVDKANLEIMTKRSNYTPITNVPPEVTVLTNSPVELREPNVLICFI
DKFT 
PPVVNVTWLRNGKPVTTGVSETVFLPREDHLFRKFHYLPFLPSTEDVYDCRVE
HWGLDE  
short: 
PLLKHWEFDAEND 
long: 
PLLKHWEFDAPSPLPETTENEND 
Protein 
MW 
AS: 21,264;  AL: 22,330 Da 
Protein pI AS: 4.75;  AL: 4.67 
Protein 
extinction 
coefficient 
28,000 at 280nm (unfolded) 
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A.15 HLA-DR1 beta gene sequence 
 
 
Gene 
Construct 
HLA-DR1 B1S (β chain, short) and B1L (β chain, long) 
Plasmid Full length in pHN1 (T7 promoter) called pDRB10 
Short version in pLM1 (T7 promoter) 
Amp resistance gene for plasmid production in E. coli  
Made by Mia Rushe in Larry Stern’s Lab 
Sites used 
for cloning 
EcoRI and HindIII 
Insert size ~600bp B1S, ~620bp B1L 
For 
production 
in 
E. coli BL21 
Induce with IPTG 
Gene 
Sequence 
xgaattcaggaggaatttaaaatgGGGGACACCCGACCACGTTTCTTGTGGCAGCTT
AAG 
TTTGAATGTCATTTCTTCAATGGGACGGAGCGGGTGCGGTTGCTGGAAAG
ATGCATCTATAACCAAGAGGAGTCCGTGCGCTTCGACAGCGACGTGGGG
GAGTACCGGGCGGTGACGGAGCTGGGGCGGCCTGATGCCGAGTACTGG
AACAGCCAGAAGGACCTCCTGGAGCAGAGGCGGGCCGCGGTGGACACCT
ACTGCAGACACAACTACGGGGTTGGTGAGAGCTTCACAGTGCAGCGGCG
AGTTGAGCCTAAGGTGACTGTGTATCCTTCAAAGACCCAGCCCCTGCAGC
ACCACAACCTCCTGGTCTGCTCTGTGAGTGGTTTCTATCCAGGCAGCATT
GAAGTCAGGTGGTTCCGGAACGGCCAGGAAGAGAAGGCTGGGGTGGTGT
CCACAGGCCTGATCCAGAATGGAGATTGGACCTTCCAGACCCTGGTGATG
CTGGAAACAGTTCCTCGGAGTGGAGAGGTTTACACC 
short: 
TGCCAAGTGGAGCACCCAAGTGTGACGAGCCCTCTCACAGTGGAATGGA
GAGCAtaaaagctt long: 
TGCCAAGTGGAGCACCCAAGTGTGACGAGCCCTCTCACAGTGGAATGGA
GAGCACGGTCT GAATCTGCACAGAGCAAGtaaaagctt 
Protein 
Sequence 
iqeefkMGDTRPRFLWQLKFECHFFNGTERVRLLERCIYNQEESVRFDSDVGEY
RAVTELGRPDAEYWNSQKDLLEQRRAAVDTYCRHNYGVGESFTVQRRVEPK
VTVYPSKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVSTGLIQN
GDWTFQTLVMLETVPRSGEVYTCQVEHPSVTS  
short: 
PLTVEWRAEND 
long: 
PLTVEWRARSESAQSKEND 
Protein 
MW 
B1S: 22,185;  B1L: 23,059 Da 
Protein pI B1S: 5.98;  B1L: 6.23 
Protein 
extinction 
coefficient 
38,930 at 280nm (unfolded) 
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A.16. Primers used to generate point mutants in HLA-DR1 
 
L45A Forward: GACGGTCTGGCGGGCTGAAGAATTTGGAC  
Reverse:          GTCCAAATTCTTCAGCCCGCCAGACCGTC 
 
F48A Forward: GGCGGCTTGAAGAAGCTGGACGATTTGCC 
Reverse:          GGCAAATCGTCCAGCTTCTTCAAGCCGCC 
 
F51A Forward: GAAGAATTTGGACGAGCTGCCAGCTTTGAGG 
Reverse:          CCTCAAAGCTGGCAGCTCGTCCAAATTCTTC 
 
S53A Forward: GAATTTGGACGATTTGCCGCCTTTGAGGCTCAAGGTG 
Reverse:          CACCTTGAGCCTCAAAGGCGGCAAATCGTCCAAATTC 
 
F54A Forward: GACGATTTGCCAGCGCTGAGGCTCAAGGTG 
Reverse:          CACCTTGAGCCTCAGCGCTGGCAAATCGTC 
 
Beta W153A: CCAGAATGGAGATGCGACCTTCCAGACCC 
Reverse:        GGGTCTGGAAGGTCGCATCTCCATTCTGG 
 
Beta F89A: CTACGGGGTTGGTGAGAGCGCAACA 
Reverse:    CAACTCGCCGCTGCACTGTTGCGCTC 
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A.17 Using Fluorescence Polarization to measure KDapp and Peptide off 
rates 
 
Determination of KDapp 
Reagents: 
 5X binding buffer (bb) 
 -500mM NaCitrate pH 5.0 
 -250mM NaCl 
-0.5% Octylglucaside 
-25mM EDTA 
-0.2% Azide 
-note: add 5mM DTT and protease inhibitors to1X just prior to use. 
Black low binding polystyrene 96 well plate 
12 channel pipette from Mauricio 
Alexa-488 labeled peptide 
Purified empty DR 
 
Set up: 
1. Add 100ul 1x bb to wells a-f 2-12 
2. Add 200ul 250nM DR1 (in 1xbb) to wells a-f 1 
3. Serially dilute by taking 100ul from a-f 1 and mixing it with next set of wells. 
Continue to wells a-f 11, but leave a-f 12 with no DR1 
4. Add 100ul 1x bb to wells a-f 12 (note: polarization values are not reliable if you 
don’t have at least 200ul volume) 
5. Add peptide (HA-FRR alexa 488)to all wells (I added 50ul/well of 250nM 
peptide for a final concentration of 25nM/well) 
6. Seal plate and incubate in the dark at 37º for 3 days. 
7. Read by polarization (set gain equal to peptide only well) 
8. Fit to the following equation modified from the “Saturation binding with ligand 
depletion”  under the advanced radioligand binding file in GraphPad Prism 
Kd=KdnM  
b=Kd + X + Bmax 
c=-1*X +Bmax 
Y=(-b+sqrt(b*b-4*a*c) )/(2*a)  
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Effect of DM on peptide dissociation: 
 
Set up: 
1. Add 100ul 1x bb to wells a-f 2-12 
2. Add 200ul 600nM DM (in 1xbb) to wells a-f 1 
3. Serially dilute by taking 100ul from a-f 1 and mixing it with next set of wells. 
Continue to wells a-f 10, but leave a-f 11 and 12 with no DM 
4. Add 100ul of 200nM DR1 to all wells except a-f 12, to those wells, add 100ul 
1x bb 
5. Add peptide (HA-FRR alexa 488) to all wells (I added 50ul/well of 250nM 
peptide for a final concentration of 25nM/well) 
6. Seal plate and incubate in the dark at 37º for 3 days. 
7. Read plate for time 0 
8. Add 100x cold peptide (unlabeled HA-FRR) to all wells 
9. Read plate (I set the plate reader up to scan every minute for 30 minutes then 
every 10 minutes for 3 hours) I also read the plate once/day for another 3 days 
until my peptide was competed off. 
10. Data were fit to a one phase exponential decay  
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